Low - Versus High- Dose Oxytocin for Labour Augmentation by Babekir, Hassan
University of Khartoum 
Graduate College   
Medical & Health Studies Board 
Low - Versus High- Dose Oxytocin 
for Labour Augmentation 
By 
Dr . Hassan Babekir Ziada Mohammed 
MBBS. University of Al-Azhar (1994) 
A thesis submitted in partial fulfillment for the requirements of the Degree of Clinical 
M.D in Obstetrics and Gynaecology, May 2002  
 
 
 
Supervisor 
Professor Abdel Salam Gerais 
MD , FRCOG  Professor of Obstetrics & Gynaecology U of K  
                                          
 
  
CONTENTS 
 
                                                                                                          page      
Dedication………………………………………………………..    I 
 
Acknowledgement ……………………………………………….   II  
 
Abbreviations …………………………………………………….   III 
 
Arabic Abstract ………………………………………………….    IV 
 
English Abstract  …………………………………………………..  V 
 
List of Tables ……………………………………………………..   VI 
 
List of Figures……………………………………………………..   VIII 
 
                                         
CHAPTER ONE 
 
Introduction ……………………………………………………….    1 
 
Literature Review………………………………………………….     4 
 
Objectives ………………………………………………………….    32 
 
                                          
CHAPTER TWO 
 
Materials and Methods………………………………………………   33 
 
 
                                        CHAPTER THREE 
Results………………………………………………………………..   37 
 
 
                                      CHAPTER FOUR 
Discussion……………………………………………………………   86 
Conclusion and Recommendation …………………………………...   90                            
References…………………………………………………………….   91 
Appendix  
  
 
 
 
Dedication 
 
 
 
 
 To My Parents Who Have Been Supporting Me All 
The Time. I’m So Grateful For Their Help, 
Patience and care to make this work a reality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               
Acknowledgement 
 
 
 
           I would like to express my deep gratitude to the Consultants in 
new Omdurman Maternity Hospital, the house officers, midwives & all 
staff for their grate participation & assistance in this work. 
        My sincere appreciation to my supervisor professor Abdel Salaam 
Gerais for his guidance & useful help which kept me in direction of the 
study objectives. Without his advice and supervision this study would 
have been defective. 
         I would like to acknowledge the help of Mr.Isam in statistical 
 analysis & Miss Sahar in correcting, categorizing & typing the 
manuscript, also I extend my thanks to Miss Wafa, educational counselor 
at The British Council.  
 
 
 
 
 
                                                                                                                                  
   
List of Abbreviations 
 
 
 
ACOG         American Collage of Obstetrics and Genealogists 
 
ARM           Artificial Rupture of Membranes 
 
CPD            Cephalo pelvic Distress  
 
Cm/hr         Centimeter per hour   
 
FD               Fetal Distress  
 
Hrs              Hours  
 
mU/min      mili unit per minute  
 
PGDH         Prostaglandins  
 
PROM        pre-Labour Rupture of Membranes  
 
UK             United Kingdom  
 
USA           United State of America  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                
 
Abstract 
   
           
                        One hundred and forty nine consecutive pregnant women 
under labour augmentation for ineffective slow labour New Omderman 
Maternity Hospital in the period from March30, to October 2,2000 were 
included in this study. We prospectively compared a low-dose oxytocin  
protocol with high-dose one in terms of their effectiveness and safety. 
The low dose protocol was used in seventy four(49.7%) pregnancies and 
high-dose protocol in seventy five pregnancies950.3%) during the six 
months study period. 
            Labour duration was 4 hours shorter (p=0.544) with the high-dose 
regimen, but no adverse maternal and fetal effects were observed. No 
significant differences were found in the modes of delivery between the 
two protocols. 85.9% delivered vaginally, (5.4%) by ventose or forceps 
and (8.7%) by cesarean delivery. 
         No perinatal deaths were encountered and those needed 
resuscitation or admission to nursery were mainly delivered through 
operative routes compared to the spontaneous vaginal one (p=0.000 
significant).  
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CHAPTER ONE  
INTRODUTION 
 
  
              The augmentation of labour is a common prevailing obstetric 
policy. It is frequently used in obstetric practice to correct the abnormal 
pattern of ineffective slow labour. It means stimulation of inefficient 
uterine contraction after spontaneous onset of labour.  
  
         Until 1970s, the problem was considered troublesome, but since 
then it has become widespread routine as a part of a movement, 
associated in particular with National Maternity Hospital Dublin, Known 
as Active Management of Labour. While debate raised between 
proponents and opponents, of the active management of labour (or at least 
of its two components, amniotomy and oxytocin augmentation), it rapidly 
moved into routine use, especially in English speaking countries. In 
United States, the use of the procedure was supported by Emmanuel 
Friedman invention of so called partogram; where slow labour declared 
by alert and action lines. The idea is that if labour was slow these lines 
would be crossed and intervention by amniotomy and oxytocin should 
follow.  
 
          Our aim is to reduce the rate of dystocia and consequently 
operative deliveries achieving vaginal delivery as close as possible to the 
natural one without subjecting mother or fetus to more hazards.  
             Definitely, the procedure is not without harm as opponents 
always claim. Hyperstimulation of uterus and resultant abnormal fetal 
heart rate pattern are most common complication that usually necessitate 
modification of the dose rather than complete ceasation of the procedure.  
 
Moreover few studies showed oxytocin augmentation occasionally had 
caused fetal hypoxaemia, hyperbilirubinaemia, hyponatraemia and 
maternal hyponatraemia.  
 
       To date, no universal agreed upon method has come to use 
concerning our subject. For instance, in Dublin and most UK obstetric 
departments they have used early amniotomy and oxytocin infusion 
whenever labour is slow since 1970s. Many in USA do augmentation 
with oxytocin infusate set-up and simultaneous amniotomy as in this 
study. Few prefer late amniotomy and oxytocin infusion when the cervix 
dilated 4 cm or more for fear of infection and a stratified belief that early 
amniotomy and oxytocin will delay labour. No one uses oxytocin alone 
with intact membranes as a method of labour augmentation as this may 
probably end up with amniotic embolism. Additionally, such practice 
may miss the biological advantage of amniotomy.  
       
 Currently, the most effective way to augment and accelerate the latent 
phase of labour artificially is by local administration of prostaglandins 
(PGs) and the duration or frequency of exposure to this agent will depend 
on how far the cervix is ripened, a measure which is best made by Bishop 
score assessment. Our ability to intervene effectively has improved 
steadily with our improved understanding of biological control of human 
labuor. The three intervention currently available are prostaglandins 
which is best administrated vaginally, amniotomy which is ideally done 
when cervix fully effaced and 3 to 4 cm dilated, and oxytocin which is  
best administered by intravenous titration. This order represents the 
logical sequence of their use.  
           In current study, we sought to determine the effectiveness and 
safety of low-dose oxytocin regimen, recommended by (ACOG), 
compared to high-dose oxytocin in augmentation of ineffective labour.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LITERATURE REVIEW 
 
Historical background of labour augmentation:  
                   Over 300 years, the purchase to introduce a method for labour 
stimulation began when Thomas Denman of the Middle Sex Hospital in 
1956 has made a major turn by introducing amniotomy as a method of 
labour stimulation. This method has remained a cornerstone of labour 
stimulation to the present time (Calder, et al)(1).      
                    The isolation of oxytocin by Sir Henry Dale made a glorious 
progress in labour stimulation. In 1909 the first studies carried by 
William Blair on the isolated oxytocin had led to the use of this magic 
hormone in labour stimulation over the next few decades. In 1948 
Theobald et al used oxytocin in infusion set with fixed dose (probably 
low) to stimulate labour. The advent of pure synthetic oxytocics (e.g. 
syntocinon) has enabled oxytocin to be used more effectively to stimulate 
labour.  
                       In 1963, Kieran O’Driscoll of Dublin described a policy of 
labour stimulation named collectively active management of labour. It 
composed of four components (strict criteria for labour diagnosis in 
primigravidae, commitment to never leave a woman unattended in labour, 
early amniotomy and oxytocin augmentation if progress is slow i.e. 
cervical dilatation at rate <l cm/hr). He claimed that it lowered the rate of 
cesarean section and instrumental deliveries, was safer for the baby and 
popular with mothers.  
      
                
 Since 1970s the policy (or at least two of its components early 
aminiotomy and oxytocin augmentation) has become a routine 
management of slow labour in parturients of low parity. 
Contemporaneous with that, the traditional management of soap and 
water enema, hot bath and cinnamon and castor oil was recommended as 
a method of stimulation of labour though it dated over 400 years. This 
combination particularly stimulates contractility of smooth muscles of 
gastrointestinal tract and in some women may simultaneously have 
stimulated myometrial contractions possibly by release of endogenous 
prostaglandins (PGs) from gastrointestinal tissues (Calder et al)(2).    
 
Definition of labour augmentation:  
                (ACOG) defined labour augmentation as stimulation of uterine 
contractions when spontaneous contractions have been considered 
inadequate with resultant failure of progressive cervical dilatation or 
descent of the fetus. Some also consider augmentation to include 
stimulation of contractions following spontaneous rupture of membranes 
without labour (ACOG)(3).    
 
When is labour augmentation indicated:  
             The major indication for labour augmentation as stated by (Cohen 
and Friedman)(4)  is uterine hypotonia i.e. insufficient uterine contractions 
during active phase of labour. (Reynolds and co-workers)(5)  emphasized 
that uterine contraction of normal labour are characterized by gradient of  
 
 
 
 
myometrial activity being greatest and lasting long at fundus (Fundal 
dominance) and diminishing towards the cervix. 
 
            Although more than 50% hypotonic uterine dysfunctional labour 
no obvious cause was detected (Seitchik and co-workers)(6), the remaining 
percentage encountered with primigravidae, cephalopelvic disproportion 
(CPD), fetal malposition and malpresentation. In rare circumstances over-
distention of uterus by twins or hydramnios may contribute to the 
condition as well as rigid cervix either primary (as in senior primigravida) 
or secondly to fibrosis from some cause.  
 
           Also labour augmentation indicated to achieve cervical dilatation 
at rate more than that occurs in normal labour. This is usually needed 
when vaginal delivery is prompted to minimize the risk that could affect 
the mother or fetus if labour prolonged. Example for that is an abruptio 
placenta, although uterus may be hypertonic, especially when cervix is 
well effaced and considerably dilated. The use has been challenged 
against the base that it might enhance the escape of thromboplastin into 
maternal circulation. This has been disgarded by (Pritchard)(7) .  
 
                The use of oxytocin augmentation for hypertonic uterine 
dysfunction (frequent in- co-ordinate contractions) did convert to the 
orderly physiological contraction (Caldeyro-Bracia)(8) . But in general, the 
likelihood of such response is low &risk of enhancing hypertonia is 
considerable (Cohen and Friedman)(4) .  
 
 
 
 
              The procedure is prohibited when no abnormality arises during 
the normal progress of labour (1 cm/hr) because the intervention may 
cause delay and harm rather than hasten and decrease the labour time. 
Also it is contraindicated if there is a contraindication of vaginal delivery 
as in placenta praevia, overt cephalo-pelvic disproportion, transverse lie 
and pelvic obstruction. In other occasions it should be used with high 
caution in grandmultiparae, over-distended uterus, abruptio placentae and 
previous uterine scar.  
 
Incidence:  
                The change in obstetric practice in late 1960s and earl 1970s 
rose the rate of prolonged labour that subjected to augmentation up to 
more than 40% in some countries e.g. USA (Satin et al)(9) . Williams 
reported “ in nearly 20-30% of all pregnancies, woman show difficult 
labour and require labour to be augmented”. In United States, there are 
approximately 4 million deliveries per year and consequently there are 
approximately 1millon such labour augmentation representing 25% 
augmentation rate.  
 
              In Ottawa of Canada (Stewart and colleagues)(10) reported 30% of 
3740 women with labour were given a diagnosis of dystocia and under 
went augmentation.  
 
               In developing countries (Dujordin and co-workers)(11)  described 
in Senegal an augmentation rate of 13% to abnormal labour progress  
 
 
 
 
showing lower incidence than in developed countries.  
              In parkland hospital at Dallas, USA approximately 22% of 
labour is stimulated by oxytocin, and from 1983 to 1990 approximately 
20,000 women were given oxytocin.  
 
             The labour augmentation rates are now increasing probably 
because of either over diagnosis of dystocia or women have developed a 
reproductive disadvantage led to elevation in rate of dystocias incidence.  
 
              A similar incidence of augmentation was described by  ( Boyle  
et al )(12) and (Cardozo et al )(13)  in excess of 40%.  
 
             A low rate of 19.3% was documented at Royal North Shore 
hospital in Sydney, Australia with a rate of 21.8% over all hospitals 
(Mothers & Babies Report)(14) .   
 
Recommendation and guidelines to labour augmentation:  
              Experience has taught the care-deliverers in Parkland Hospital at 
Dallas, as well as many obstetric centers in USA and UK to state clearly 
general as important as specific recommendation that hopefully guide to 
fruitful end of labour augmentation work up:  
 
1) General:  
              The hazard and risks of augmentation should be weighed against 
waiting for spontaneous vaginal delivery. The indication of augmentation 
should be outlined and clear discussion and disclose of risk factors 
(including anticipated obstetrical risk, advantages and limitation of  
 
 
 maternity care services and transport risk) with the pregnant woman and 
her husband prior to augmentation, and informed consent should be 
obtained.  
                Assessment with documentation prior to staring augmentation 
should include:  
 
• Uterine activity: its frequency and duration.  
• Fetal heart and wellbeing.  
• Fetal presentation.  
• Pelvic adequacy.  
• Cervical dilatation, effacement and consistency (Bishop score).  
 
             A qualified registered nurse, familiar with the effects of 
augmentation agents and able to detect both maternal and fetal 
complications, must be available throughout augmentation.  
 
 
2) Delivery of specific care:  
             When augmentation of labour is contemplated, it is important that 
the responsible physician considers where the best conditions can be 
provided for the mother during labour and delivery and for neonatal care, 
and then refers the patient if advisable. Consideration must be given to 
the following: 
 
- Availability of adequately equipped labour and delivery area with 
appropriate resuscitation equipment for both mother and newborn.  
 
- Availability of appropriately trained labour and delivery nursing 
staff to monitor the fetal heart rate, maternal condition (pulse, BP 
….etc) and uterine contraction every 15-30 minutes throughout 
augmentation (Nurse: Patient ratio should be 1:1)  
 
             There is no evidence –based information indicating that operating 
room be a requisite for augmentation of labour. However clinical data 
states that augmentation of a nullipara is associated with twice the chance 
of cesarean delivery compared with spontaneous labour.  
 
                 It is incumbent on rural facilities without cesarean delivery 
capability to determine their local practice and procedure regarding 
augmentation of labour and indications for patient transfer. These 
decisions should take into consideration indications for augmentation, 
antenatal risk factors, method of augmentation, geographic &climatic 
consideration which are all vary from patient to another.  
                   
A tocolytic agent must be available in the event of hypertonic 
uterine contractions.   
 
 
Methods of labour augmentation:  
 
               In literature there are two known methods of labour stimulation; 
surgical and medical. In the past they were considered separate, but in 
modern obstetrics this separation is artificial. (Beazley)(15)  claimed that  
according to a stratified literature, the surgical method (amniotomy) or 
medical one (oxytocin) alone can stimulate labour satisfactory when  
conditions are optimal. Unless both methods used in combination the 
duration of labour remains uncertain.  
 
               While many protocols are widely available & acceptable the use 
of amniotomy in combination with oxytocin infusion is generally 
advocated. Oxytocin infusion is the only drug currently used for labour 
augmentation.  
 
                    Utilization of this approach rapid delivery can be obtained in 
majority of women. Concerning, (Beazley)(15)  said that the ideal method 
for stimulating labour would be one which could produce contraction as 
close as to normal physiological uterine contractions as possible, be free 
from deleterious effects on mother or fetus and be easy and practical to 
use.  
 
                     Recently, in addition to oxytocin use of labour augmentation 
prostaglandins gain popularity in developed countries as the component 
of the speedometer of labour use to accelerate and ripen the cervix during 
the latent phase and consequence augmentation of myometrial 
contractions. 
 
AMNIOTOMY:  
                      The artificial rupture of membranes (A.R.M.) is an old non-
pharmacologic method of labour stimulation and promotion. The 
procedure first introduced by (Thomas Denman,1758) to induce labour. 
Since then, it has become a popular practice in labour rooms of the vast 
majority of hospitals. It promotes labour by the release of endogenous 
prostaglandin in response to local stimulation. In some cases when labour 
is so advanced and Bishop score is high it may be possible to augment 
labour simply by amniotomy. This successfully works more likely in 
multiparous women than primiparae. 
 
                   The approach is particular preferred in grandmultipara 
because of the fear that oxytocin drugs might cause hypotonic uterine 
contractions and consequent disasterous rupture.  
 
                       When amniotomy and oxytocin infusion were the standard 
methods labour augmentation, as in active management of labour, all 
women had amniotomy early and was followed by oxytocin infusion if 
cervical dilatation was slow (less than 1cm/ hr). In certain high-risk cases 
amniotomy may be beneficial to allow early internal fetal monitoring 
when labour ensures. Other wise evidence has shown no overall 
significant benefit of early amniotomy and the membranes can safely be 
left intact until close to delivery unless progress is abnormal (cammu et 
al).(16)  This will minimize the risks of dry labour namely signs of infection 
and cord entanglement that necessitate surgical interference.  
 
              Two decades ago (Patterson)(17)  and (Saleh)(18)  carried out studies 
comparing amniotomy with oxytocin infusion versus amniotomy alone 
favourable cervix lead to a shorter delivery interval, fewer operative 
interference and higher proportion of women delivered with 24 hours 
than with amniotomy alone. This indicates amniotomy alone is often  
inadequate to stimulate and augment labour. In cases studied by (Moldin 
et al)(19)  amniotomy combined with oxytocin infusion resulted in delivery 
interval of 6 hours compared to 9 hours with amniotomy alone. In 
amniotomy combined with oxytocin infusion group 88.7% and 97.7% 
delivered within 12 hours and 24 hours respectively while in cases of 
amniotomy alone 70.4% and 91.8% delivered within 12hours and 24 
hours respectively. In cases studied by (Patterson)(17)  and (Saleh)(18)  
instrumental delivery was 25% and 50% respectively.  
 
                         When the concept is which to start first the amniotomy or 
oxytocin infusion, (Rayburn)(20)  thought it is better to commence oxytocin 
infusion then did amniotomy while (Calder)(1)  was reluctant to give 
oxytocin infusion before amniotomy as it greatly increases the sensitivity 
of myometrium to oxytocin.  
 
OXYTOCIN:  
              Oxytocin has been used for induction of labour for well over half 
a century and remains the major drug for medical augmentation of labour. 
It is an octa peptide hormone released naturally by the posterior pituitary 
gland. Its main action is to stimulate uterine contractions. According to 
the American college of obstricias and Gynaecologists (ACOG)(3)  
oxytocin levels required to produce effective contraction vary widely 
among individual, most likely reflecting unpredictable individual uterine 
sensitivities, variabilities in clearance rates and any pre-existing uterine  
 
 
 
 
 
 
activity. The increase in myometrial oxytocin receptors appears to explain 
the increased sensitivity to oxytocin with increasing gestational age. The 
result of the study conducted by (Fuchs et al )(21)  was in accordance with 
the (ACOG). It showed concentration and distribution of oxytocin 
receptors in myometrial and decidual tissues obtained at hysterectomy or 
cesarean deliveries during pregnancy. It was found that myometrial 
receptors concentration was low at 13 - 17 weeks of pregnancy and rose 
about twelve – fold by 37- 41 weeks after onset of labour. After onset of  
labour either term or preterm, the receptor levels were maximal and 
significantly higher than before labour onset. Myometrial receptor 
concentration in the fundus and the corpus were significantly higher than 
in the lower part of uterine segment and the cervix had the lowest 
concentration. These results - according to the author - are consistent with 
the functional role of endogenous oxytocin in the activation of the human 
uterus during pregnancy and parturition.  
 
Dosage and administration:  
                 Oxytocin infusion for labour stimulation was firs described by 
(Theobald et al.,)(22) (23) (24) in 1948. Since then multiple protocols have been 
suggested. However oxytocin titration method introduced by (Trunbull 
and Anderson) in 1967 is considered the best regimen for oxytocin 
administration.   
 
 
 
 
 
 
 
             The intravenous route is solely the efficient way as subcutaneous, 
intramuscular or intranasal routes are considered inadequate to administer 
oxytocin for augmentation of labour.   
 
             Now, different mechanical and electronic controlled systems and 
pumps are used to adjust the oxytocin infusion rate and dosage. The best 
acceptable one is variable speed pump not gravity fed-drip. The latter 
may accumulate oxytocin in its bottom resulting in bolus infusion, so it 
should be mixed thoroughly every now and then. The former pulsatile 
method, titrated as individual response, dose closely simulate the 
physiological pattern of oxytocin release during spontaneous labour, by 
pumping the drug in 10 minutes pulse infusion.  
 
               The recommended protocols were designed to give lower doses 
of oxytocin at longer interval. According to ((ACOG) technical 
bulletin)(25)  labour stimulation with high dose oxytocin regimen has no 
advantage over a more physiologic low- dose protocol. The high-dose is 
associated with increased risk of uterine hyperstimulation while the low - 
dose in association with slow rate infusion (Increments interval 30 – 60 
minutes) were found appropriate and safe. A fact which was also 
concluded by (Goni et al)(26)  who studied oxytocin increments at 20and 60 
minutes interval.  
 
            Similar results were obtained by (Satin et al.,)(27) (28)  when studied 
both low dose and high dose regimens in 1992 and high regimen 20-40  
 
 
 
minutes intervals in 1994. Also in accordance the conclusion reached by 
(Hourviz et al)(29)  in assessing high versus low dose oxytocin for labour 
stimulation.  
 
The recommended protocol:  
Low-dose protocol:  
              The dose of oxytocin is measured in milliunits (mU) per minute 
based on a standard preparation. The standard infusion concentration, as 
recommended by (ACOG) is 10 units of oxytocin diluted in 1000 ml 
(10mU/ml) of isotonic electrolyte solution usually Hartmanns solution – 
using starting dose of (0.5-2mU/min) with (1-2mu/min) increments every 
30-60 minutes. The solution may be Hartmanns/dextrose or Normal 
saline according to availability and medical need. Forty (40) minutes of 
continuous infusion of a fixed dose of oxytocin is required to reach a 
steady state of plasma concentration (Satin et al.,).(28)  However, failure to 
quickly determine the therapeutic dose of oxytocin significantly increase 
the length of labour and augmentation-delivery time, More than 87% will 
achieve satisfactory uterine activity with (< 4mU/min) while more than 
95% will do so with (7mU/min) of infused oxytocin. The dose 
requirement of a term uterus rarely exceed 20mU/min.  
 
High-dose protocol  
                     In this protocol they use starting dose of (3-6 mU/min) with 
doubling of the infusion rate and dose every (20-40 minutes).  
 
 
 
 
 The maximum rate to reach is not more than (42 mU/min), (Satin et 
al.,).(9)  For doses exceeding (16 mU/min) fetal heart rate auscultation for 1 
minute to 30 second periods after contraction should be done. Secondly, 
hourly maternal pulse and blood pressure should be checked (more 
frequently if indicated). If infusion exceeding 24 hours or other infusions 
are in place, measure serum electrolyte and pay particular attention to 
serum sodium concentration. Also the event of uterine hypertonus 
complication more frequently occurs with this high-dose protocol and so 
the resultant fetal distress.  
 
Prostaglandins (PGs):  
                   PGs firs appeared in the medical literature in 1968 by (Karim 
et al.,).(30)  They used Prostaglandin E2 and F2  for induction of labour. 
Since then (PGs) use has gained enoromous success in clinical 
environment for both cervical ripening and subsequent labour stimulation 
various formulations have been tried in the trials.  
 
             The role of prostaglandins in the reproductive system was heavily 
explored. It is now realized that the PGs members of the group of 
prostanoids, which include also thromboxanes, are probably involved in 
most organs function. They are a family of highly active and structurally 
similar modified unsaturated fatty acids. The group of primary (PGs) 
consists of six members formed by conversion of 3 precursor essential 
unsaturated fatty acids. In reproduction (PGE2) and (PGF2) appear to be  
 
 
 
 
 of major significance and are formed from arachidonic acid via the 
cycloendoperoxides (PGG2) and (PGH2) following the influence of the 
cyclo-oxygenase enzyme system. 
                     They are rapidly metabolised via 15- hydroxy prostaglandin 
dehydrogenase and 13-reductase enzymes which are widely dispersed in 
the body.  
 
                     Although the precise function of (PGs) in the evolution of 
spontaneous parturition remains uncertain, there is convincing evidence 
that they are essential for initiation and normal progress of labour.  
                      (Calder)(2)  stated that in a normal term pregnancy (PGs) are 
activated to provoke cervical ripening and myometrial contractions. 
Increase in (PGs) and their metabolites have been demonstrated both in 
late pregnancy and during cervical dilatation in advanced labour.  
 
                     (Slade et al)(31)  mentioned that they probably act via a second 
mesenger at the amniotic membrane level, which is a rich source of 
arachidonic acid and also to sensitize myometrium to oxytocin. 
Therefore, the use of (PGs) to stimulate labour may thus be considered 
appropriate.  
 
                  There is also a (PGs) surge in the third stages of labour which 
highly likely contributes to the expulsion of the placenta and membranes. 
It helps, therefor, in prevention of postpartum haemorrhage. It was shown 
by (Kennedy et al)(32)  that the incidence of primary postpartum 
haemorrhage appears to be reduced if (PGs) are used as part  
 
 
 of the induction procedures rather than oxytocin alone and that the potent 
oxytocic effect of (PGs) make them of value in the management of 
postpartum haemorrhage. PGs became available in the late 1960, as 
Dinoprost (PGF2) and Dinoprostone (PGE2). The latter is about 5 times 
as potent as Dinoprost in stimulating uterine activity.  
 
                 (Beazley and Alderman)(33)  concluded that neonatal 
hyperbilirubinaemia which can be associated with maternal oxytocin 
infusion of more than 20 units does not appear to be a problem with the 
use of (PGE2).  
 
                Various commercial formulations of (PGE2 = Dinoprostone) 
are now available. The oral and intravenous routes have been abandoned 
because of their side effects, which are related to systemic absorption. 
They are largely supplanted by the local route. The intarvaginal route is 
the one of chioce as it is preferred by both women and clinicians. 
Different protcols, doses and formulations have been tried. They are 
prone to a variety of influences, which may affect absorption. This was 
seen by (Lyndruo)(34)  who reported that quickly absorbed (PGE2) in wax-
based vaginal pessaries is likely to soon cause uterine contractions where 
as PGE2 in low-dose or slowly absorbed preparation, as intracervical gel 
or vaginal lactose tablets, is more likely to only ripen the cervix. The 
ACOG in 1995 recommended intracervical route because it offers the 
advantage of prompting little uterine activity and greater efficacy in very  
 
 
 
 
unripe cervix, but (Calder)(2)  considered it inconvenient use. Indeed, 
intracervical application is hardly possible, because the intracervical 
space is either tiny or open widely and gel leakage to the vagina or 
extramniotic space is more likely and this in turn may produce intense 
myometrial activity. On the other hand, the extra –amniotic 
administration of (PGE2) is thought as effective method of interrupting 
pregnancy because it delivers (PGE2) to the internal cervicalos, the 
region of the cervix from which effacement arises. But, because of its 
invasive nature and more possible uterine hyperstimulation it is not much 
advocated.  
 
                    The recent introduction of a controlled released PGE2 intra 
vaginal insert (cervidile = 10mg Dinoprostone) for cervical ripening and 
labour stimulation has stimulated much interest. The vaginal insert 
provides a lower rate of release than the gel and can be removed should 
hyperstimualtion occur.  
 
                     In a comparative study done by (Rayburn et al.,)(35)  in USA, 
cervidil was found more effective in ripening the cervix and intiating 
active labour by the end of 12-hour dosing period without requiring 
additional oxytocin in both multiparous and mulliparous women when 
compared to multiparous women given multidose of intravaginal PGE2 
gel.  
                    From analysis of oxford data base perinatal trials (Calder)(2)  
stated that it became clear that (PGs)could consistantly improve Bishop  
 
 
 
score, reduce length of labour, reduce cesarean section rate and improve 
neonatal outcome.  
 
                   The duration of labour was shown to be shorter in most of the 
studies (Mackenzie et al.)(36)  reported a mean of 8.1 hours (hrs) in 
primiparae and 4-8 (hrs) in multiparae, while (Calder)(2,1)  shown a mean 
of 10.7 hrs. The length of labour was found in cases studied by 
(Shephered et al.,)(37)  7.8 (hrs) for primiparae and 5.1 hrs for multiparae.  
 
              Uterine hyperstimulation is a serious complication it occurs in 5- 
6% more following (PGs) administration than oxytocin to women 
undergone labour stimulation and occurs more frequently in active phase 
of labour.  
                   Maternal systemic side effects from low-dose (PGE2) (fever, 
vomiting and diarrhea) are negligible as shown in the report of the 
(ACOG technical bulletin).(25)   
 
Misoprostol (PGEI analogue):  
                  Very recently this drug has received increased attention as 
effective cervical ripening agent. Originally, misoprostol was developed 
as an oral drug to treat the gastrointestinal ulceration. It has the advantage 
of being inexpensive, easy to store at room temperature compared to the 
expensive PGE2 preparations.  
 
                   In a comparative study done by (Buser et al)(38)  between 
misoprostol and dinoprostone (PGE2) it was found that the former is  
 
 
 
 more effective in ripening the cervix and stimulating labour. Adversely, 
misoprostol caused an increase in cesarean deliveries and associated with 
uterine hyperstimulation rate of 35.5% compared to 21.5% for 
dinsoporstone group.  
 
               (Alfirevic et al.,)(39)  reviewed five randomised controlled studies 
of oral misoprostol versus other methods for stimulating labour. He 
concluded Oral misoprostol versus placebo reduces the need for oxytocin 
infusion and shortens the time between stimulation of labour and 
delivery. The cesarean deliveries were found 20.2% in oral misoprostol 
group compared to 15.5% in case stimulated by vaginal (PGE2).  
 
The uterine hyperstimulation which is a serious side effect of oral 
misoprostol was found in 37.5% of case compared to 28%for vaginal 
misoprostol.  
 
 Hazards and risks of labour augmentation:  
               Augmentation of labour is not free of hazards both to the mother 
and fetus. The assessment of factors that my lead to these hazards is 
crucial. The risks include:-  
 
(1) Uterine hyperstimulation:  
                There is risk of 1% of uterine hypertonus when labour 
stimulated by Oxytocin infusion or prostaglandins and 0.2% risk of 
sustained tetanic contractions of uterus necessitating urgent tocolysis or 
immediate cesarean delivery (Slade et al).(31)  If not, this will lead to fetal  
 
 
 distress and most serious fetal loss and uterine rupture. This is usually the 
case with prostaglandins (PGs) administration as modulation or stoppage 
of oxytocin infusoin will commonly lead to gradual disapearance of 
uterine hypertonus. It occurs in 35.5% with misoprostol and 21.5% with 
dinoprostone (Buser et al., )(38)   (Satin et al.,)(27)   stated incidence of 52% 
of uterine hyperstimulation for high-dose and 34% for low-dose oxytocin 
augmentation in study of 2788 consecutive pregnencies. It was occurring 
5-6% more with prostaglandin than with oxytocin. The uterine 
hypertonus, by itself, is not necessarily pathologic regarding its outcome. 
The common associations with this risk are inadequate assessment of the 
fetopelvic disproportion degree, malpositiopn and malpresentation of the 
presenting part.  
 
                  In the event of uterine hypertonus, usually seen in association 
with high dose regimens, i.e. six contraction in 10 minutes, contraction 
duration for more than 90 seconds pre-signs of fetal distress; the 
following should be done immediately:-  
 
- Stop oxytocin infusion.  
 
- Change maternal position and correct hypotension.  
 
- Administer oxygen by facemask.  
 
- Consider intravenous salbutamol or Ritodrine administration.  
 
 
 
            When uterine hypertonus or fetal distress has resolved resume the 
oxytocin infusion at half the previous rate. Increase will be after 30 
minutes only if there has been no further evidence of uterine 
hypertonicity or fetal distress. Moreover, in the presence of recurrent 
severe variable or late decelerations consideration should be given to fetal 
scalp blood sampling for pH.  
 
(2) Fetal distress:  
                Fetal distress (F.D) occurs when fetus deprived from its oxygen 
requirements (fetal hypoxia) causing the affected one to reflexely grasp in 
muconeum. This is the case when labour is prolonged or uterus is 
hyperstimulated. (El –Quarmalawi et al )(40)  repoted in a study of labour 
stimulation by PGE2 versus oxytocin a 16% incidence of fetal 
bradycardia with oxytocin leading to immediate cesarean delivery. (Satin 
et al)(27)  reported an incidence of 4% with oxytocin augmentation.  
 
(3) Infection:  
                It constitutes a little appreciable risk in obstetric practice as 
amnionitis can always be detected with prolonged labours more than 30 
hours after amniotomy.  
 
(4) Neonatal hyperbilirubinaemia:  
                It is a well-recognized risk of high dose oxytocin administration 
during labour especially in a prolonged one. The role of oxytocin 
administration during labour in aetiology of neonatal hyperbilirubinaemia  
 
 
 
 
has been a subject of much discussion especially in British literature. 
Many investigators have confirmed the association between the use of 
oxytocin and neonatal hyperbilirubinaemia.  Initially, no mechanism was 
identified to explain clearly the cause of oxytocin – related 
hyperbilirubinaemia until lately (Buchan)(41)  concluded that it is the 
vasopressin-like action of oxytocin that cause osmotic swelling of 
erythrocytes leading to decreased deformability and some rapid 
destruction. Maternal and neonatal hyponatraemia caused by the above 
action can be minimized or preferably prevented by the use of saline or at 
lesser extent glucose with saline as vehicle for oxytocin. (Leylek et al.,)(42). 
Also, dexamethasone injection is used as a prophylaxis from RBCs 
destruction and sudsequent neonatal hyperbilirubinaemia.  
 
                 Despite of the above hazards, babies delivered with low Apgar 
scores are reported to be trivial and when so there is often a cause, which 
is actually not related to oxytocin infusions. Apgar score at 5 minute and 
less than 4 was found in 6 cases out of a large number of 1976womem 
augmented by (Satin et al.,)(27) . (Seitchik and Castillo)(43)  reported 3 
neonates of 1-minute Apgar score less than 7 of 129 augmented cases, 
each has specific aetiology and was unrelated to oxytocin infusion (cord 
entanglement, mid-forceps extraction and epidural anaesthesia –
associated with maternal hypotension). In the same study they found no 
neonate with 5- minute Apgar score less than 8. The percentage is little 
higher with oxytocin induction as described by (Hourviz, et al.,)(29)  who  
 
 
 
 
 
 found 1 minute Apgar score <7 in 4.8% of 179 cases, and 5-minute Apgar 
score <7 in 5% of cases induced by (Krammer et al).(44)   
 
               In oxytocin augmented patients, in spite of prolonged labour, on 
significant increase in asphyxial perinatal death, neonatal seizures and 
abnormal neonatal neurological behaviour in 30.874 term primigravidae 
(Cahill et al)(45) . Also, (Akoury et al.,)(46) (47)  had the same conclusion in a 
controlled prospective study of 1080 nulliparae, that no satisfactory 
significant birth asphyxia or perinatal morbidity between augmented 
group (high-dose oxytocin) and non-oxytocin group (Thorp et al.,)(48) 
showed that on adverse effect of high-dose oxytocin augmentation on 
umbilical cord blood gas values at delivery.  
 
(5) Need for analgesia:  
                Augmented labours increased the need for analgesia and 
subsequent impact in labour duration with high incidence of instrumental 
delivery and cesarean section.   
 
(6) Failure of augmentation and operative delivery:  
             This usually results from failure to progress due to an overlooked 
fetopelvic disproportion, dystocia, chorioamnionitis or fetal distress that 
urge cesarean delivery (Satin et al.,)(27)  declared a rate of 14.5% of 
cesarean section and 14% of instrumental deliveries for failure or 
augmentation.  
 
 
 
 
                      The failure to progress means failure of active uterine 
contractions (Active phase of labour) to dilate the cervix over a 
reasonable period of time (Raybun)(20)  denoted at least 2 hours period 
while (Dwight et al)(49)  extended oxytocin augmentation for active phase 
labour arrest to at least 4 hours before resorting to operative delivery. 
They found it was effective and safe with 92% of 542 women delivered 
vaginally compared with 83% vaginal deliveries when time restricted to 
only two hours.  
 
Reasons of failure of augmentation:  
                    Failure of Augmentation has been attributed to many factors 
influencing the process and course of labour. The factors thought to be 
involved include the type of oxytocin regimens used, primiparit, high 
maternal age, the type of augmentation method, lack of oxytocin 
receptors and poor selection of patients.  
 
A) Oxytocin regimen type:  
                  Low-dose Oxytocin regimens with long incremental intervals 
are associated with less augmentation failure rates due to less incidence of 
uterine hyperstimulation 33% & fetal distress 4% (Seitchil & Castillo)(43) 
and (Satin et al).(27)   Contrariwise, the cesarean section rate for dystocia in 
relation of oxytocin dose regimens & incremental intervals was 12% for 
low-dose regimen with long incremental intervals (40- minutes) versus 
9% for high-dose regimen with short intervals (20- minutes). In contrast 
the incidence of uterine hyperstimulation 55% and fetal distress 6% are  
 
 
 increased with high-dose oxytocin with short incremental intervals and 
resultant increase in cesarean section rates. High-dose oxytocin regimens 
shortened labour up to 3 hours (Satin et al)(27)  but did not lower cesarean 
or instrumental deliveries in meta-analysis of randomized controlled trial 
of 5.100 women with slow labour (Dwight et al.,).(49)  same of trials 
suggested high-dose oxytocin regimens increased the need for epidural & 
prolongation of labour (Dwight et al.,)(49)  with the resultant liability for 
cesaran section.  
 
B) Primiparity:  
                As in normal labours, parous women in augmented labours tend 
to have a shorter course of labour than nulliparae. This fact has 
highlighted the necessity of reviewing nulliparous and multiparous 
women as biologically different groups in term of labour performance. 
The cervix in nulliparous women will not dilate to 4cm before it has 
already been effaced, where in multiparae cervical dilatation of 4cm often 
occurs before effacement is complete. The nulliparous women are the 
largest group with firm rigid cervix which increases the likehood of failed 
augmentations or prolonged exhausting labour. (Moldin et al)(19)  reported 
a difference in success rate of labour stimulation by amniotomy and 
oxytocin; 94.9% for multiparae achieved vaginal delivery within 12hours 
compared to 79.4% for the nulliparous women. The difference was found 
to be bigger in a similar group of patients stimulated in the same study by  
 
 
 
 
amniotomy alone with higher success in multiparae because of already 
dilated cervix.  
 
C) The Type of Augmentation method:  
                     (Seitchik et al.,)(6)  demonstrated that aminiotomy alone 
appeared to enhance dilatation of well-dilated cervices and slowed that of 
less dilated ones. The failure rate was as high as 20% to achieve a 
satisfactory dilatation rate (1 cm or more/hr) when aminiotomy alone was 
used. The combination of aminiotomy and oxytocin infusion especially in 
less-dilated cervices leads to high rate of vaginal deliveries 88.7% 
compared to 70.4% for aminiotomy alone (Moldin et al.,)(19)  fewer 
instrumental deliveries 25% to 50% respectively (Patterson)(17)   & 
(Salih).(18)      
 
 
D) Insensitive Target organs:  
                       The women in whom failure of progress of stimulated 
labours was encountered, the level of circulating oestradiol concentration 
were found to be lower than those with successful stimulated labours 
(Marchenzie)(36) . This may not facilitate the rise in Prostaglandin F2 (PGF) 
metabolic in circulation which appears to be necessary for progressive 
labour to occur. On other hand (Calder)(I)  pointed out that in some cases 
whereas the cervix is firm, rigid and thick (unfavorable) there may well 
be an excess of (Prostaglandin dehydrogenate) (PGDH) activity or some 
enzyme activities that contribute to an unfavorable cervix. Likewise,  
 
 
 
 
 women in preterm labour may have (PGHD) deficiency provoking their 
labour process. 
 
E) Lack of oxytocin receptors:  
                       (Fuchs et al)(21)  found a relation between oxytocin receptors 
in human uterus and failed stimulation of labour. He studied 
concentration and distribution of oxytocin receptors in myometrial and 
decidual tissues obtained at cesaerean section or hysterectomy during 
pregnancy. He found that after the onset of labour, either preterm or term, 
the receptor levels are maximal and significantly higher than before 
labour onset. While in cases of failed stimulation of labour with oxytocin 
the levels were significantly lower tan in spontaneous normally 
progressing labour.  
 
F) High maternal age:  
                      (Lyndup)(34)  listed high maternal age as one of the predictive 
factors related to disadvantageous labour stimulation. Fetal malposition is 
more common in such old ladies and so are fetal malpresentation and 
both predispose to failed stimulation of labour. Mechanical factors that 
delay and obstruct labour should be excluded before the decision of 
augmentation is made.  
G) Inappropriate selection of patients:  
                  Inappropriate selection of women undergoing augmentation of 
labour without clear indication-as hyptonic uterus-was found to be a  
 
 
 
 reson for failure of progress. (Arulkumaran et al)(50)  studied 1057 cases 
subjected to stimulation. They analyzed the indications for stimulation 
and revealed that a fair number of cased had debatable obstetric 
indications. Also, they suggested that tailoring stimulation of labour to 
cervical score and indication might reduce the cesarean section rate for 
failed progress of labour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OBJECTIVES 
 
A) General: 
      To assess the effectiveness and safety of low- compared to high- dose 
protocol in augmentation of labour.  
 
B) Specific : 
 
1- To determine the incidence of uterine 
hyperstimulation  
                       and fatal distress in both protocols. 
 
   2-                To measure the duration of labour in each protocol. 
 
3-                To determine the rate of operative delivery (C/S  
                       and instrumental delivery) in both groups.    
 
 
 
 
 
 
 
 
 
 
  
CHAPTER TWO  
MATERIALS & METHODS 
 
 
 
                  This experimental study was carried out at New Omdurman 
Maternity Hospital, in the period from March 30, to October 1,2000. The 
hospital is especially designed as maternity institute supported by 
Khartoum State ministry of health. The hospital capacity is around 110 
beds. The nearly twenty Obstetrics & Gynaecology house officers and 
seven registrars are supervised by seven consultants. Annually, not less 
than four thousand deliveries take place in the hospital. The number of 
total deliveries within the period of the study was 1976. The study 
population consisted of women attending the lobour ward for delivery.  
             One hundred forty- nine parturient were selected to the study. 
The inclusion criteria were pregnant women who had gestational age of 
37 to 43 weeks, singleton pregnancies with cephalic presentation with no 
contraindication to augmented vaginal delivery and were given diagnosis 
of ineffective labour as her cervix at least 3-4cm on admission and did not 
dilate progressively within two hours.   
                    Pregnancies complicated by viscous meconium, sever 
hydramnios, or parity of five or more were excluded. All subjects were  
 
 
 
 
 
 
 
admitted to labour room and selected randomly to one protocol of 
oxytocin augmentation. Our study of low-versus high-dose oxytocin 
protocols for labour stimulation consisted of low-dose protocol which 
begins with I mU/min, dose and incremental increases of I mU/min at 30-
minute intervals up to 6 mU/min, then 2mU/min incremental, increases 
up to 12mU/min, then 4 mU/min increments up to a maximum 
40mU/min. The high-dose protocol included a starting dose of 3 mU/min 
at 30 minute intervals with 3mU/min increments up to 12mU/min, then 
6mU/min increments at the same intervals up to a maximum 42mU/min. 
 
                The incremental increase was reduced from 6 to 3 mU/min in 
the presence of uterine hyperstimulation after halving the reaching dose. 
Recurrent hyperstimulation was managed by ImU/min oxytocin 
increments. All pregnancies eligible for labour stimulation during the 6 
months study period were managed according to these protocols. 
 
             The whole procedure and aim of the study were well explained to 
each parturient and written consent of agreement was taken. All were 
seen by a consultant obstetrician and gave permission for the procedure. 
 
            For data collection, a details standard, questionnaire was 
designed. The history notes, the clinical review and examination of each 
subject as well as labour diagnoses were all carried out by the author.  
 
 
 
 
 
 
            The infusate prepared by the author, for either regimen comprised 
2 units of synthetic oxytocin (syntocinon) diluted in 500 ml of 5% 
glucose with 0.9% solution given concentration of 4 mU/ml, the regimen 
was administrated by house officers specially trained for that purpose. 
Oxytocin infused by drop drip-set in a rate according to the intended 
protocol. Assuming that I ml = 20 drops, we started low-dose regiment 
with 5 drops/min (I mU/min)  and high-dose regimen with 15 drop/min 
(3mU/min) every 30 minutes till 3 contractions of 30-45 sec duration 
each in 10 minutes were achieved. The infusate was turned off in the 
presence of uterine hyperstimulation 6 contractions or more, or duration 
of 90 seconds or more in 10 minutes or fetal heart rate abnormalities. 
Oxytocin was readjusted to one-half the previous dose and then titrated 
after 30 minutes interval at half rate. 
 
                 The progress of labour was monitored on WHO designed 
partogram. The fetal heart rate was monitored by intermittent auscultation 
every 30 minutes in the first stage, and every 5 minutes in the second 
stage of labour.  
 
                 The labouring women were nursed throughout the first stage in 
the lateral position. Oral fluids were some time allowed. Sedation and 
analgesia were given per need. Bishop score was recorded before the 
commencement of the procedure; we chose the cervical assessment as 
determining component of successful labour stimulation (Williams  
et al) (51). Reassessment of the cervix performed after 2 or 4 hours after  
 
 
 
augmentation, with bearing down and full dilatation of the cervix the 
parturient was transferred to the delivery table and vaginal delivery  
managed by the senior mid-wife on duty in the lithotomy position. 
Instrumental delivery was indicated for fetal distress, maternal exhaustion 
or prolonged second stage of labour.  
             Cesarean section was performed for fetal distress in the first stage 
of labour, maternal complications necessitating immediate delivery or 
failure of progress. The failure of augmentation was considered if the 
uterine contractions had not led to further cervical dilatation during active 
phase of labour over at least 4-hours period.  
              Perinatal records was filled and completed by the attending 
house officer including the mode and time of delivery, neonate weight, 
Apgar score at 1-and 5-minutes after delivery, if resuscitation and 
admission to the nursery was necessary. 
            The placenta was delivered by controlled cord traction. The 
patient was a observed for 2 hours after delivery in the labour ward before 
her transfer to postnatal ward where most of the patients were discharged 
on the next day. 
        The data was collected in a discrete, transferred to a master sheet, 
coded and fed to a microcomputer. Statistical analysis was performed 
using the computer statistical package minitab. 
      Appropriate statistical tests were used for comparable variables. X2 
test and fisher exact test of probability were used stratification of data 
controlling for demographic variables were achieved where appropriate. 
Two –tailed P values of 0.05 or less were considered significant. 
 
 
CHAPTER THREE 
 
 
RESULTS 
 
               A total of 149 women required one of the two syntocinon 
protocols 91.9% of the ages were within 20-34 years with a mean of 27.4 
years for the whole study group (Table1, Fig.1). Most of the women were 
housewives 92.6%and only 7.4% employee. 
 
            All pregnancies were term cited between 37 and 42 weeks. Except 
5 women (3-4%) who were post-term dating more than 42 weeks. While 
age, occupation and parity had nothing to do with the mode of delivery, 
the gestational age was the only character of pregnancy that significantly 
affect the mode of delivery (Table 2,3). 
 
           The significance between nulliparae and high-dose; and primiparae 
or more and low-dose may be attributed to the process of randomization 
and/or the feeling of safety among the staff when they relate the low-dose 
to primiparae or more and vice versa (Table4, Fig.4). This was shown by 
a higher rate of cesarean delivery among post-terms (Table5, Fig.3). 
 
         On the other hand, the dilated cervices (59.7%) and subsequent high 
Bishop scores were (more than 4, 94%) significantly associated with high 
vaginal deliveries (Table 6&7). 
          It was found that the cervical assessment was highly significant 
(P=0.000) than Bishop score (P=0.023) indicating that the former is the 
most important factor in predicting the expected vaginal delivery.  
 
 
 
 
These cervices were assessed again after the intervention administrates by 
one of the protocols. Most of them were improved (96.6%) and only 5 
cases (3.4%) showed no improvement. Consequently, this was reflected 
on a high significant rate of vaginal deliveries (85.9%) (JP=0.000)   
(Table 8,Fig.5). 
More than half of the remaining 5 cases, which showed no improvement, 
ended by cesarean delivery (Table 8). Moreover, it was found no relation 
between the protocol used and the cervical improvement (Table 9). 
 
            Significantly, larger doses were used in high-dose group (Table 
10). Three cases required more than 30 mU/min, two of them had 
cesarean deliveries (Table 11). 
 
            The time consumed to reach the maximum dose of syntocinon 
was insignificantly shorter in high-dose protocol (Table 12).  
 
           This resulted in a shorter duration of labour in the high-dose group 
than the low-dose one; but significantly at expense of an increased rate of 
uterine hyperstimulation (14.1% Vs 25.5%) (P=0.020) (Table 13 & 14). 
However, uterine hyperstimulation resulted in insignificant fetal heart rate 
abnormalities (2.7% vs 2.6%) that urged immediate operative delivery 
(instrumental or cesarean), no adverse neonatal effects were observed 
after delivery (Table 13 & 15; Fig. 6 &7). 
 
          The syntocinon infusion, in the presence of uterine 
hyperstimulation, was modified rather than completely stopped. The 
modification was significantly higher in high-dose group (12.7% vs 
24.1%) (P=0.004) (Table 16 & 17) (Fig. 8 & 9). Most of the cases 
(69.1%) required a maximum dose of less than (8 mU/min) in both 
protocols (43% vs. 26.2%) (P=0.000) while only 2% required more than 
(30mU/min) which entirely cited in high-dose group (Table 10, Fig.10). 
 
There was a significant inverse correlation between the maximum 
dose and the probability of attaining vaginal delivery. Of 103 cases who 
required less than (8 mU/min), 101 delivered vaginally (Table 11);  
 (P=0.000). 
 
Duration of labour was insignificant shorter by 4 hours in high-
dose group (Table 14, Fig.11) (P=0.544). The mean duration for the high-
dose was 8 hours and for the low-dose was 12 hours. 
                
  A total of 128 women delivered vaginally constituted (85.9%) of 
whole study group. No significant difference was found between the two 
protocols (41.6%) vs.44.3%) (Table 19, Fig.12). 
 
There were 8 light ventose or forceps delivery equal to (5.4%). 
Five were in low-dose (3.4%) and there were in high-dose (2%) (Table 
19, Fig.12). The indications were 4 suspicious fetal distress(2.7%) and 4 
(2.7%) for maternal complications either due to maternal exhaustion or 
medical problem. The low incidence of instrumental delivery among the 
high-dose group was insignificant (Table 19).  
 
The incidence of cesarean delivery among the study group was 
(8.7%), with (4.7%) among low-dose and (4%) among high-dose group.  
 
 
 
The variation between two groups is trivial and insignificant (Table 19, 
Fig. 12). 
 
             The cesarean delivery indications were 4 for fetal distress (2.7%), 
1 for maternal exhaustion and distress (0.6%) and 8 for arrest of labour 
(5.4%). The syntocinon protocol had no significant influence in 
developing these indications (Table 21, Fig. 13). 
 
            These indications significantly affected the mode of delivery as 
dystocia was entirely led to cesarean delivery and maternal exhaustion 
was almost managed by instrumental delivery (Table 21 & 22, Fig. 13 
&14). 
 
           Again high-dose protocol was indirectly and, more important, 
insignificantly associated with low cesarean section for dystocia and low 
instrumental deliveries for maternal complications (Table 21, Fig. 13). 
 
             Post delivery maternal complications occurred in 3 cases, one in 
low-dose and another 2 in high-dose. They occurred within the first 6 
hours after delivery. One was minor post-partum haemorhage (<1,000ml) 
due to retained placental tissue in a women delivery vaginally. She was 
treated by manual removal of the tissue and ergometrine. No blood 
transfusion was needed. The remaining two were vaginal and cervical 
tears due to the  forceps delivery treated by successful haemostatic 
sutures. This correlation between postpartum complications and forceps 
deliveries was highly significant (P=0.000) while no relation to the 
protocol used (P=0.633). 
 
 
            All babies were born alive. No neonatal death reported in the 
study group. No 1 min Apgar Score less than 4 was recorded. Three cases 
of high-dose protocol (2%) had 1 min Apgar Score equal to 4, however, 
no case of 1 min Apgar Score equal to 4 reported in low-dose group 
(Table 23) (P=0.006). Moreover, 1 min Apgar Score of 4 was 
significantly found in operative deliveries (2 instrumental (1.3%) and 1 
cesarean section (0.6%) (Table 24). Fortunately, after 5 minutes no score 
less than 8. The 5 babies (3.4%) who scored 8, 3 (2%) were 
insignificantly in high-dose group (P=0.504) and 4 (2.7%) were 
significantly operative deliveries (2 (1.3%cesarean section) (Table25) 
(P=0.000). 
 
            14 neonates needed resuscitation. No significant differences 
between the two protocols regarding this need. The significant differences 
was found between modes of delivery (P=0.000) (2 (1.3%) vaginal 
delivery,5 (3.4%) instrumental delivery and 7 (4.6%) cesarean delivery) 
(Table 26, Fig. 15). 
 
              All babies who were admitted to the nursery were from operative 
route of delivery (2 (1.3%) instrumental and 2 (1.3%) cesarean) given a 
significant (P= 0.000) when compared to vaginal route (Table 27, Fig.16).  
            143 (96%) of babies weighing 3.5 kg or less while 6% weigh 
more than 3.5 kg. The fetal weight had an effect on mode of delivery 
giving significant probability of vaginal delivery when weighing 3.5kg or 
less (125 (84%) (P=0.034) (Table 28).  
 
 
 
 
    Table 1.   Age distribution among the study groups 
                        according to syntocinon protocol   
 
Age groups              Low dose                  High dose                   Total 
 (years)       
< 20                         20 (1.40%)               06 (4.00%)              008 (5.40%) 
 
20 - 34                     72 (48.3%)               65 (43.6%)              137 (91.9%) 
 
≥35                          00                             04 (2.70%)                 04 (2.70%) 
 
 
Total                       71(49.70%)              75 (50.30%)             149 (100%) 
 
 
 
Mean age =27.4 years.   
 
 
 
 
 
 
 
 
  
     Table 2. Relation between syntocinon protocol and   
                                        occupation  
 
Occupation                    Low dose               High dose               Total                             
House wives                68 (45.7%)             70 (46.9%)            138 (92.6%)  
 
Employee                   06 (04.0%)             05 (03.4%)             011 (07.4%)  
 
 
Total                          74 (46.7%)              75 (50.3%)             149 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
         
Table 3. Relation between syntocinon protocol  
                               and gestational age  
 
Gestational             Low dose              High dose                          Total  
37 – 42                   70 (46.9%)            74 (49.7%)                   144 (96.6%)  
 
> 42                        04 (02.8%)            01 (00.6%)                   005 (03.4%) 
 
 
Total                       74 (49.7%)             75 (50.3%)                  149 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 
Table 4.  Relation between syntocinon protocol and parity 
 
 
Parit                  Low dose                    High dose                     Total    
PG                     15 (10.1%)                  44 (29.5%)                   59 (39.6%)  
 
Para 1 - 4           59 (39.6%)                  31 (20.8%)                   90 (60.4%)  
 
 
Total                  74 (49.7%)                  75 (50.3%)                   149 (100%) 
  
 
  
     
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 5. Relation between gestational age and mode of delivery 
  
  
 
 
Gestational              VD                  Ventose                 CS                      Total  
                                                          Or 
 age                                                    
                                                       forceps   
37 – 42                     127                    07                     10                          144 
                             (85.2%)            (4.7%)                (6.7%)                  (96.6%)  
 
>42                          001                  001                     03                          005 
                             (0.7%)             (0.7%)               (2.0%)                    (3.4%) 
 
 
Total                        128                  8                     13                           149 
                             (85.9%)         (5.4%)              (8.7%)                    (100%)  
 
 
 
 
 
 
 
 
 
 
 
  
Table 6. Effect of pre-augmentation cervical assessment on 
mode of delivery 
 
Cervical                              VD                       Ventose or                     CS  
Assessment                                                        Forceps                 
 
Dilated 3 cm                   56 (37.6%)              2 (1.3%)                        2 (1.3%)  
 
Dilated > 3 cm                72 (48.3%)               6 (4.0%)                      11 (7.4%)  
        
 
Total                               128 (85.9%)             8 (5.4%)                       13 (8.7%)  
 
  
 
P = 0.0000 highly significant      
  
 
 
 
 
 
 
 
 
       
 Table 7.  Correlation between bishop score and  
                              mode of delivery  
 
Bishop               VD               Ventose or               C/S                  Total  
score                                        Forceps  
<4                    0                        0                          0                        0  
 
4                  006 (4.0%)            0                          3 (2.0%)           9 (6.0%)  
 
>4                 122                      8                         10                      140  
                   (81.9%)              (5.4%)                 (6.7%)               (94%)                                     
             
 
Total           128                        8                          13                     149  
                  (85.9%)              (5.4%)                   (8.7%)              (100%)           
    
 
P =0.023 Significant   
 
 
 
 
 
 
 
 
  
 
Table 8.    Correlation between cervical assessment after  
             2-4 hours augmentation and mode of delivery 
 
Cervical                   VD               Ventose or                  C/S               Total  
assessment                                     Forceps              
 
Same                     02 (1.3%)              0                      3 (2.0%)          5 (3.4%) 
 
 
Better                      126                       8                          10               144  
                             (84.6%)              (5.4%)                  (6.7%)          (96.6%)     
                                                                                          
 
Total                     128                          8                      13                    149  
                           (85.9%)                (5.4%)                 (8.7%)               (100%)  
                                                        
  
  P = 0.0000 Highly significant  
 
 
 
 
 
 
 
 
  
 
Table 9. Correlation between cervical assessment after 2 or 4 
                        hours augmentation & syntocinon protocol 
 
Cervical assessment                      Low dose                           High dose 
Same                                             02 (1.3%)                            03 (2.0%)  
 
 
Better                                             72 (48.3%)                          72(48.3%)  
 
 
Total                                             74 (94.7%)                            75 (50.3%)  
 
     
  
P = 0.506  not significant  
   
 
 
 
 
 
 
 
 
 
 
  
 
    Table 10.  Maximal dose by syntocinon protocol  
 
Dose rate                             Low dose                                High dose 
1-     6 mU/min                  64 (43.0%)                              39 (26.2%)  
 
8-    12mU/min                  06 (04.0%)                              25 (16.8%)  
 
16-  30mU/min                 04 (2.70%)                               08 (5.40%)  
 
>30  mU/min                              0                                    03 (2.0%) 
 
 
 
Total                                74 (49.7%)                              75 (50.3%) 
 
          
 
P = 0.0000 significant  
 
 
 
 
 
 
 
 
  
Table 11. Correlation between maximum syntocinon dose 
and mode of delivery 
 
Maximum Dose                     VD                    Ventose or                  CS  
                                                                          Forceps  
 
1- 6 mU/min                       101 (67.8%)             2 (1.3%)                     0  
 
8 - 12 mU/min                   024 (16.1%)              2 (1.3%)                 5(3.4%)  
 
16- 30 mU/min                  002 (1.3%)                4 (2.7%)                 6 (4.0%)  
 
> 30                                  001 (0.7%)                  0000                     2 (1.3%)  
 
 
Total                                128 (85.9%)              8 (5.4%)                13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
  
Table 12. Time consumed per hour to max. dose by  
                                    syntocinon protocol  
 
Time consumed                         Low dose                          High dose   
Per hour 
<4                                          64 (43.0%)                           42 (28.2%)  
 
4-6                                        06 (04.0%)                           25 (16.7%)  
 
>6                                        04 (02.7%)                            08 (05.4%) 
 
 
Total                                   74 (49.7%)                            75 (50.3%) 
 
 
 
P =0.0000 significant  
  
 
 
 
 
 
 
 
 
 
  
 
 Table 13. Causes of syntocinon modification or stoppage  
                                 by syntocinon protocol  
 
Cause of syntocinon                      low dose                        High dose  
No uterine or FHR                        52(34.9%)                       35(38.5%)  
abnormality  
Uterine hypertimulation               18(12.1%)                        36(24.2%)  
 
Abnornal FHR                             01(0.7%)                           02(1.3%)  
 
Uterine hypertimulation &         03(2.0%)                            02(1.3%)  
Abnormal FHR                          
 
Total                                          74(49.7%)                         75(50.3%)  
 
 
 
P =0.020  significant  
      
  
 
 
 
 
 
 
  
     
Table 14.  Correlation between duration of labour and  
                              Syntocinon protocol  
 
Duration of labours /hours                    Low dose                 High dose                  
1-6                                                          08                             32  
 
7-12                                                        54                              36  
 
> 12                                                         12                              07 
  
 
Total                                                        74                              75  
 
 
 
P = 0.544 not significant  
 
Mean duration of labour = 10 hrs  
Mean duration of labour in low dose = 12 hrs  
Mean duration of labour in high dose = 8 hrs   
 
 
 
 
 
  
 
     Table 15.    Correlation between Causes of syntocinon 
                    modification or stoppage and mode of delivery 
 
Cause of  
syntocinon  
VD   Ventose or  
      forceps 
C/S 
No uterine or FHR                  75 (50.3%)         3 (2.0%)           9 (6.0%)  
abnormality  
 
Uterine hyperstimulation          53 (35.6%)         1 (0.7%)          0   
 
Abnormal FHR                            0                      2 (1.3%)           1 (0.7%)  
Uterine hyperstimulation           
& Abnormal FHR                        0                      2 (1.3%)           3 (2.0%)  
Total   128 (85.9%)     8 (5.4%)   13 (8.7%)  
    
 
P = 0.0000 highly significant  
   
 
 
 
 
 
 
 
  
 
Table 16. Decrease syntocinon dose by syntocinon protocol  
 
 
Decrease syntocinon                     Low dose                         High dose  
Yes                                             19 (12.7%)                        36 (24.1%)  
 
 
No                                             55 (36.9%)                          39 (26.2%)  
 
 
Total                                        74 (49.7%)                           75 (50.3%)  
 
 
  
P = 0.004 significant  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
    Table 17.   Correlation between times the dose was  
                             modified and syntocinon protocol  
 
Dose modified                              Low dose                            High dose                           
1                                                     54 (36.3%)                         38 (25.5%)  
 
 
2- 3                                                 20 (13.4%)                         20 (13.4%) 
  
> 3                                                  00                                       17 (11.4%) 
  
 
Total                                               74 (49.7%)                         75 (50.3%) 
 
 
 
 
   
P = 0.0000 highly significant  
  
  
 
 
 
 
 
 
 
 
        
Table 18.   Discontinuation of syntocinon infusion by  
                                   syntocinon protocol  
 
Discontinuation                      Low dose                      High dose  
Yes                                         05 (03.4%)                    06 (04.0%)  
 
 
No                                         69 (46.3%)                     69 (46.3%)  
 
 
Total                                     74 (49.70%)                   75 (50.3%)  
                              
 
 
P = 0.498 not significant  
 
 
 
 
   
     
   
 
 
 
 
 
         
 
Table  19.   Association between mode of delivery  
                                   and syntocinon protocol  
 
Mode of delivery                       Low dose                    High dose  
Vaginal delivery                        62 (41.6%)                    66 (44.3%)  
 
 
 
Forceps or Ventose                  05 (03.4%)                      03 (02.0%)  
 
 
C/S                                            07 (04.7%)                      06 (04.0%)  
 
 
 
Total                                         74 (49.7%)                     75 (50.3%)  
 
 
 
 
P = 0.415 Not significant  
 
 
 
 
 
  
 
Table 20. Sedation need in relation to syntocinon protocol  
 
Decrease syntocinon                    Low dose                       High dose  
Yes                                               25 (16.7%)                    50 (33.6%)  
 
 
No                                              49 (33.0%)                      25 (16.7%)  
 
 
Total                                           74 (49.7%)                      75 (50.3%)  
 
 
 
P = 0.0000 Significant  
     
 
 
 
 
 
   
  
 
  
 
 
  
 
        Table 21.   Operative delivery indications by   
                                    syntocinon protocol  
 
Operative indication                  Low dose                           High dose   
FD                                              4 (2.7%)                            4 (2.7%)  
 
 
Maternal complication              3 (2.0%)                             2 (1.3%)  
 
 
Arrest of labour                        5 (3.3%)                               3 (2.0%)  
 
 
Total                                        12 (8.0%)                              9 (6.0%)  
 
 
 
P = 0.845 Not significant  
 
 
 
 
 
 
 
 
  
Table 22. Operative delivery indications by mode of delivery  
 
 
Operative indication                        Ventose or Forceps               C/S  
FD                                                      4 (2.7%)                             4 (2.7%)  
 
 
Maternal complication                      4 (2.7%)                              1 (0.6%)  
 
 
Arrest of labour                                  0                                        8 (5.4%)  
    
 
Total                                              8 (5.4%)                                 13 (8.7%)  
 
 
 
P = 0.0000 significant  
 
   
 
 
 
 
 
 
 
  
  Table 23. One minute Apgar score by syntocinon protocol  
 
1 min Apgar score                           Low dose                       High dose  
 
4/10                                                 00                                    03 (2.0%)  
 
6/10                                                 06 (4.0%)                        02 (1.3%)  
 
8/10                                                 61 (41.1%)                        70 (47.0%)  
 
10/10                                                70 (4.6%)                         00  
 
 
 
Total                                                 74 (49.7%)                       75 (50.3%)  
                     
 
 
P = 0.006 significant  
 
 
 
 
 
 
 
  
    Table 24. One minute Apgar score by mode of delivery  
 
Apgar score                          VD                   Ventose or                        CS  
At 1 min                                                         forceps 
4/10                                         0                      1 (0.6%)                      2 (1.3%)  
 
6/10                                002 (1.30%)              3 (2.0%)                      3 (2.0%)  
 
8/10                               120 (80.6%)               3 (2.0%)                      8 (5.4%)  
 
10/10                              006 (4.00%)               1 (0.6%)                         00  
 
        
 
Total                              128 (85.9%)               8 (5.4%)                    13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
  
   Table 25. Five minute Apgar score by mode of delivery  
 
Apgar score                      VD                     Ventose or                 CS  
At 5 min                                                       Forceps                     
 
8/10                           001 (0.6%)                2 (1.3%)              02 (1.3%)  
 
 
10/10                       127 (85.3%)                6 (4.0%)              11 (7.4%)  
 
 
Total                        128 (85.9%)                8 (5.4%)              13 (8.7%)  
 
 
  
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 26.  Need for resuscitation by mode of delivery 
 
Resuscitation                   VD                       Ventose or                 CS  
Need                                                               Forceps  
 
Yes                              002 (1.3%)                 5 (3.4%)                07 (4.6%)  
 
No                               126 (84.6%)               3 (2.0%)                 06 (4.0%)  
 
 
Total                           128 (85.9%)                8 (5.4%)                 13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 27.   Admission to nursery by mode of delivery 
 
Admission to                      VD                    Ventose or               CS  
Nursery                                                          forceps         
 
Yes                                     00                    2 (1.4%)                   02 (1.3%)  
 
 
No                                 128 (85.9%)          6 (4.0%)                   11 (7.4%)  
 
 
Total                            128 (85.9%)            8 (5.4%)                  13 (8.7%)  
 
  
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 28.  Correlation between  Birth weight and mode of  
                                         delivery  
 
Birth weight (kg)           VD              Ventose or Forceps           CS  
 
≤ 3.5                           125 (83.9%)             7 (4.8%)                 11 (7.4%)  
 
 
 
> 3.5                          003 (2.00%)               1 (0.6%)                 02 (1.3%)  
 
 
Total                         128 (85.9%)                8 (5.4%)                  13 (8.7%)  
 
     
 
 
P = 0.034 significant    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1) Age distribution among 
the study groups
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Fig. (2) Relation between syntocinon 
protocol and occuption
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Fig. (3) Relation between gestational 
age and mode of delivery
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 Fig. (4) Relation between 
syntocinon protocol and parity
15
44
59
31
0
10
20
30
40
50
60
70
Low dose        High dose       
syntocinon protocol
Nu
m
be
r 
o
f c
as
es
 
(W
o
m
en
)
Primi gravida
Para 1 - 4          
  
 
 
 
 
 
 
 
Fig. (5) Correlation between cervical 
assessment after 2-4 hour 
augmentation and mode of delivery
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 Fig. (6) Causes of 
syntocinon modification or 
stoppage by syntocinon 
protocol
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Fig. (7) Correlation between 
causes of syntocinon modification 
or stoppage and mode of delivery
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Fig. (8) Decrease syntocinon 
dose by syntocinon protocol
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Fig. (9) Correlation between times 
the dose was  modified and 
syntocinon protocol
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Fig. (10) Maximal dose reached 
by syntocinon protocol
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Fig. (11) Correlation between 
duration of labour and syntocinon 
protocol
8
32
54
36
12
7
0
10
20
30
40
50
60
Low dose        High dose       
syntocinon protocol
N
u
m
be
r 
o
f c
as
es
 
(W
o
m
en
)
1 – 6 hours
7 – 12 hours
> 12 hours            
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12)   Association between mode 
of delivery and syntocinon protocol
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Fig. (13)  Operative delivery 
indications by syntocinon protocol
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 Fig. (14) Operative delivery 
indications by mode of delivery 
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 Fig. (15)  Need for resuscitation by 
mode of delivery 
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Fig. (16)   Admission to nursery by 
mode of delivery
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CHAPTER FOUR  
DISCUSSION 
 
 
  
              To our knowledge, the purpose of this experimental study was to 
answer the question which oxytocin-dose regimen is beneficial to 
augment labour? The answer is both. 
              High-dose oxytocin clearly had several advantages when used to 
augment ineffective labour. Labour duration was 4 hours shorter with 
high-dose than low-dose infusion. This is not far from the one quoted by 
(Satin et al.)(27)  in a similar study. He reported more than 3 hours shorter 
with high-dose regimen. A similar result stated by (Bidgood)(52) &  
(Steer).(53)   
The seemingly high rates of uterine hyper-stimulation in both study goups 
reflect adherence to a onservative and precise definition of uterine hyper-
stimulation as contractions of 2 minutes’ duration or greater; or six or 
more contraction in 10 minutes. This definition is taken by most obstetric 
units in UK and USA (Satin et al .,).(27)  Although labour augmentation 
with high-dose was associated with sigificantly more frequent uterine 
hyper-stimulation (14.1%vs.25.5%); there is no apparent adverse 
maternal or fetal sequale from this as (Cahill et al.,),(45) (Hourviz et al.,)(29)  
and (Satin et al.,)(27)  confirmed this finding.  (Satin et al.,)(27)   descibed 
incidence of (39% vs. 52%); (P<0.0001). The rate of abnormal fetal heart 
rate sounds in the form of late or variable bradycaridia, or severe 
tachycardia (>180 b/min)was the same for both groups (2.7%). 62.5% of 
these abnormal patterns were significantly associated with uterine hyper- 
 
 
 
 
 stimulation confirming their significant correlation (P=0.020). Compared 
to (Satin et al.,)(27) , incidence of fetal heart rate abnormalities was 
significantly different in both groups being 3% for low-dose-similar to 
our result- and 6% for high-dose.(Bidgood et al.,)(52)  described 1.7%  for 
high-dose in association of 37% of uterine hyper-stimulation. These 
differences may reflect deferent sensitivities to occurrence of  uterine 
stimulation among the same three studies (low-versus high-dose oxytocin 
uterine hyper-stimulation is dependent on the uterine density of oxytocin 
receptors which differ from patient to another.  
 
               Majority of patients delivered vaginally and spontaneously (not 
by instrument) 85.9%. (14.6%) in low-dose and 44.3% in high-dose. 86% 
delivered within the first 12 hours; most of them primigravidae. The 
difference was significant between two protocols regarding labour 
duration of 6 hours or less being the majority in high-dose group 
(21.4%vs.5.4%). The bulk was in low-dose group (44.3% vs.28.9%) 
when labour lasted more than 6 hours (Cardozo et al.,)(13) , (Satin et al .,)(9)  
and (Bidgood) (52)    & ( Steer)(53)    had similar reports.  
 
             The patients delivered by vetose or forceps were 8 giving rate of 
(5.4%). (3.4%) in low-dose versus (2%) in high-dose. The indications 
were fetal distress (50%) and maternal exhaustion (55%). (Satin et       
al.,)(27) desdcribed rate of around (4% vs.3%) (Bidgood) (52)   &( Steer)(53)  
gave high rates (15% vs. 13%) most probably because of common usage of  
 
 
 
high forceps during that time. To say that high-dose reduces the rate of 
instrumental vaginal delivery it needs large randomized control trial. 
 
               The rate of c/s was 8.7 giving insignificant higher incidence 
(4.7%) among low-dose group than high-dose group (4%). In 
concordance (Boyle et al;)(12), (Cardozo et al;)(13)  and (Bidgood) (52) & 
(Steer)(53)  decided rates of (8.6%), (8.7%), (8.9%) respectively. 
 
               The close similar results, despite the different size above 
mentioned studies, support the conclusion that oxytocin augmentation 
dose not reduce the overall rate of C/S unless dystocia was strongly and 
specifically considered in association with high-dose regimen. 
 
                 The common indication was dystcia  (61.5%). (38.5%) in low-
dose and (23%) in high-dose. This might insignificantly show the reduced 
rate of c/s done for dystocia in high-dose group as clearly declared by 
(Satin et al.,)(27) and before that (O'Discoll et al.,)(54) . In contrast, high-
dose augmentation did not increase the incidence of cesareans done for 
fetal distress (2.7% vs.2.7%). 
 
                Age of the patient and her parity will affect the rate  of cesarean 
deliveries in both groups. Nulliparas are younger; usually have long 
labours, less cervical score and rigid not tested pelvic floor leading to 
high possibility of cesarean delivery. The (Calder et al.,)(1)  supported that, 
as viewing nulliparae (usually young) and multiparae (usually old)     as 
biologically different groups in respect of labour performance, since  
 
 
 
the cervix in nullipara will not dilate before it is effaced where in 
multipara cervical dilatation of 4 cm often occurs before effacement is 
completed. Hence, the former is more liable to c/s than the latter. 
 
                 As in the literature, no perinatal deaths can be attributed to 
oxytocin augmentation and hence is our study. There was some degree of 
neonatal morbidity. Low Apgar scores were greatly and significantly 
referred to instrumental vaginal deliveries (1.3%) and less likely to 
cesarean section. No low morbid score found with vaginal deliveries, 
which needed admission to the nursery. Higher number of the babies 
delivered by operative means needed resuscitation and in some, 
admission to the nursery than those delivered by normal vaginal route. 
This may be interpreted by that the operative delivery was frequently 
used for already distressed baby, in addition to the risk of the procedure 
itself. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
CONCLUSION & RECOMMENDATIONS 
 
 
                   The results of this clinical trial indicate that labour 
augmentation with a high-dose oxytocin is clearly superior to a low-dose 
protocol. Although high-dose protocol associated with high rate of uterine 
hyperstimulation, it shorted labour without adverse affects on mother or 
baby. 
                   There is no difference between low-and high-dose protocols 
as far as mode of delivery is concerned. Vaginal delivery occurred in 
most of women followed by cesarean and instrumental deliveries, 
successfully. 
                   Neonatal resuscitation or nursery admission is mainly 
attributed to the operative delivery rather than the dose used. This is 
probably due to the cause of the operative intervention. 
                   This  small randomized trial of a group of women in slow 
inefficient labour highlights the need for a large randomized control  
 double blinded study to support its claims.  
                    In our set-up, it is strongly recommended the introduction 
and usage of oxytocin-infusion pump to overcome the technical 
difficulties encountered in the dose adjustment and concentration. 
This will avoid the occurrence of haemodilution, hyponatraemia and 
hence the neonatal hyperbilirubinaemia.     
 
    
   
 
REFERENCES  
 
 
1.  Calder AA. Methods of induction of labour. In: Studd J, editor. 
Progress in Obstetrics and Gynecology, 2nd ed. Philadelphia: 
Churchill Livingstone; 1983. p.86-100.  
2.   Calder AA. Review of PGs use in labour induction. Br J Obstet 
1997; 104 (Suppl. 15): 1-7. 
3.  ACOG. American College of Obstetricians & Gynaecologist.  
Induction & Augmentation of Labour. Tech Bull 1991;31:  345-49.  
4.   Cohen W, Friedman EA, editorials. Clinical management of fetal 
hypoxia. Management of Labour, 2nd ed.  Blatimore: University Park 
Press; 1983.p. 163-188. 
5.   Reynolds SRM, Heard OO, Bruns P, Hellman LM. Multichannel 
strain gauge to kodynamometer: an instrument for studying patterns 
of uterine contraction in pregnant women. Bull Johns Hopkins Hosp 
1948; 82:446.  
6.   Seitchik J, Amico J, Robinson AG, Castillo M. Oxytocin 
augmentation and dysfunctional labour. Am J Obstet Gynecol. 1984; 
150: 22-8.  
7.   Pritchard JA, MacDonald PC, editorials. Induction of labour. 
William’s Obstetrics and Gynaedology, 16th ed. New York: W.B. 
Saunders;  1980.p.790.  
8.   Caldeyro- Barcia R.  Oxytocin and pregnant uterus. Paper presented 
at meeting of the 4th pan-American Congress on Endocrinolgy, 
Buenos Aires, 1957, In: Williams Obstetrics, 19thed. Oxford: 
Appleton & Lange; 1993.p. 113-20. 
9.   Satin AJ, Leveno KJ, Sherman ML, Mclntire DD. Factors affecting 
the dose response to oxytocin for labour stimulation. Am J Obstet 
Gynecol 1992; 166: 1260.                                                                                                       
10.   Stewart PJ, Dullberg C, Armill AC, Elomstie T, Hall PF. Diagnosis 
of dystocia and management with cesarean section among 
primiparous women in Ottawa – Carletor. Can Med Assoc J 1990; 
142: 459.  
11.   Dujardin B, DeSehampheleire I, Sene H, Ndiaye F. Value of the 
alert & action lines on the partogram. Lancet  1992; 339: 1336. 
12.  Boyle DD, White RG, Ritchie JW. An assessment of active 
Management of Primigravid labour. J Med Sci  1980; 149: 456-68. 
13.  Cardozo L, Gibbo DMF, Studd JWW, Vasant RV, Cooper DJ. 
Predictive value of cervimertric labour patterns in primigravidae. Br 
J Obstet Gynecol. 1982; 89: 33-8. 
14.   NSW Mothers and Babies.  Report : part 7. Onset & augmentation 
of labour in selected hospitals. NSW health Department, Australia, 
1997.  
15. Beazley JM, editor. Special circumstance affecting labour.    
Dewhurst’s Textbook of Obstetrics and Gynaecology for 
Postgraduates, 1st ed.  Oxford: Blackwell Science Ltd; 1995.p. 585-
90.  
16.  Cammu H, Eckhout EV. A randomized controlled trial of early 
versus delayed use of amniotomy & oxytocin infusion in nulliparous 
labour. Br J Obstet Gynecol 1996; 103:313-18. 
17.  Patterson WM. Amniotomy; with or without simultaneous oxytocin 
infusion. A prospective survey.  J Obstet Gynecol  Comm  1971; 
78(4): 310 – 16.  
18.  Saleh YZ. Surgical induction of labour with or without oxytocin 
infusion: a prospective study.  Aust NZ J  Obstet Gynecol  1975;  
80-3.  
19.  Moldin PG, Sundell G. Iinduction of labour: A randomized clinical 
trial of amniotomy versus amniotomy with oxytocin infusion. Br J 
Obstet Gynacecol 1996; 103(4): 306-12.  
20.  Rayburn WF, Woods R, Eggert J. Initiation of labour with 
immoderately favourable cervix: a comparison between PGE2 gel 
and oxytocin. Int J Gynaecol Obstet 1989; 30: 225-29.  
21.   Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in 
the human uterus during pregnancy and parturition. Am J Obstet 
Gynecol 1984; 150 (6): 734-41. 
22. Theobald GW. The synthesis of divergent observations concerning 
oxytocin In: Caldeyro-Barcia R, Heller H, editors. Oxytocin, 3rd  ed.  
New York: Pergamon; 1961.p. 218-219.  
23.  Theobald GW, Graham A, Campbell J, Gange PD, Driscoll WJ. The 
use of posterior pituitary extract in physiologic amounts in 
Obstetrics. Br Med J 1948; 2: 123.  
24.  Theobald GW, Kelsey HA, Muirhead JM. The pitocin drip. J Obstet 
Gynaecol Br Emp  1956; 63(5): 641-62. 
25.  ACOG. American Collage of Obstetricians and Gynaecologists 
Technical Bulletin. induction of labour. Int J Gynaecol  Obstet 1996; 
53:56-72. 
26.  Goni S, Sawhney H, Goplan S. Oxytocin induction of labour: a 
comparison of 20- and 60- min dose increment levels. Int J Gynaecol 
Obstet 1995; 48(1): 31-6. 
27.  Satin AJ, Leveno KJ, Sherman ML, Brewster DS, Cunningham FG. 
High- versus low- dose oxytoin for labour stimulation. Obstet 
Gynecol 1992; 80(1): 111-16.  
28.   Satin AJ, Leveno KJ, Sherman ML, Mclntire D. High dose oxytocin: 
20 – versus 40- minute dosage interval. Obstet Gynecol 1994; 83(2): 
234-38.  
29.  Hourvitz A, Alcalay M, Barkai G, Korach J, Lusky A, Seidman DS. 
A prospective study of high-versus low-dose oxytocin for induction 
of labour. Acta Obstet Gynecol Scand 1996; 75(7): 636-41. 
30.  Karim SM, Russell RR, Patel RC, Hillier K. Response of the human 
uterus to PGF2. Induction of labour. Br Med J 1968; 4: 621-23. 
31.   Slade RJ, Tarid E, Beynon G, editorials.  Induction of labour. Key 
Topics in Obstet Gynecol, 1st ed.  Oxford: BIOS Scientific 
Publishers limited; 1993.p. 312-18. 
32.   Kennedly JH, Stewart P, Barlow DH, Hillan E, Calder AA. 
Induction of labour: a comparison of a sinle PGE2 vag. Tab. With 
amniotomy and I.V oxytocin. Br J Obstet Gynaecol 1982; 89: 704-7. 
33.  Beazley JM, Alderman B. Neonatal hyperbilirubinaemia following 
maternal oxytocin adminstration. Br J Obstet Gynaecol 1975; 82: 
265- 71. 
34.   Lyndrup J. PGs and induction of labour. Eur J Obstet Gynecol 
Reprod Biol 1996; 64(1): 1-2.  
35.  Rayburn WF. Clinical experience with a controlled-release, 
prostaglandin E2 intravaginal insert in the USA. Br J Obstet 
Gynaecol 1997; 104 (suppl 15): 8-12.  
36. Mackenzie R. The therapeutic roles of PGS in Obstetetrics. In: Studd 
J, editor. Progress in Obstetrics and Gynaecology, 2nd ed.  London: 
Churchill Livingstone; 1990. p.149-171. 
37.  Shepherd JH, Bennett MJ, Laurence D, Moore F, Sims CD. 
Prostaglandin vaginal suppositories: a simple and safe approach to 
the induction of labour. Obstet Gynecol  1981; 58(5): 596-600.  
38. Buser D,  Mora G, Arias F. A randomized comparison between 
misoprostol and dinoprostone for cervical ripening and labour 
induction in patients with unfavorable cervices. Obstet Gynaecol 
1997; 89(4): 581-85. 
39.  Alfirvic Z, Howarth G, Gausman A. Oral misodprostol for induction 
of labour. With available Fetus- Cochrane Review. In: the Cochrane 
Library, Issue 1, Oxford: Oxford University Press; 1991.p. 212-223. 
40. EL- Qarmalawi AA, EL Mardi M, Saddik F. A comparative 
randomized study of oral PGE2 tablets I.V. Oxytocin in induction of 
labour in patients with PROM before 37 weeks of pregnancy. Int 
Gynaecol obstet 1990; 33:115-19. 
41. Buchan PC. Pathogenesis of neonatal hyperbilirubinaemia after 
induction of labour with oxytocin. Br Med J 1979; 2:1255-257. 
42.  Leylek OA, Ergur A, Senocak F, Sencon M, Bakir S, Ozdemir H, et 
al. prophylaxis of the occurrence of hyperbilirubinaemia in relation 
to maternal oxytocin infusion with steroid treatment. Gynecol Obstet 
Invest 1998; 46(3): 164-68.  
43.  Seitchik J, Castillo M. Oxytocin Augmentation of dysfunctional 
Labor. Uterine activity data. Am J Obstet Gynecol 1983; 
145(5):526-29.  
44.  Krammer RL, Gilson GJ, Morrison DS, Morrison DS, Gonzales JL, 
Qualls CR. A randomized trial of misoprostol and Oxytocin for 
induction of labour: safety and efficacy. Obstet Gynaecol 1997; 
89(3):387-91. 
45. Cahill DJ, Boylan PC, O’Herlihy C. Does oxytocin augmentation 
increase perinatal risk in primigravid labor?. Am J Obstet Gynecol 
1992; 166(3): 847-50. 
46. Akoury HA, MecDonald FJ, Brodie G, Caddick R, Chaudhry NM, 
Frize M. Oxytocin augmentataion of labour and perinatal outcome in 
nulliparas. Obstet  Gynecol 1991; 78(2): 227- 30. 
47.  Akoury HA, Brodie G, Caddick R, Mclaughin VD, Pugh PA. Active 
management of labor and operative delivery in nulliparous women.   
Am J Obstet Gynecol 1988; 158(2): 255-58. 
48.  Throrp JA, Boylan PC, Parisi VM, Heslin EP. Effects of high – dose 
oxytocin augmentation on umbilical cord blood gas values in 
primigravid women. Am J Obstet Gynecol. 1988; 159(3): 670 - 75.  
49. Rouse DJ, Owen J, Hauth JC. Active- phase labour arrest, oxytocin 
augmentation for at least 4 hours. Obstet Gynecol. 1999; 93(3): 323-
28. 
50.  Arulkumaran S, Gibb DM, Tamby Raja RL, Heng SH, Rantnam SS. 
Failed induction of labour. Aust NZ  J Obstet Gynecol 1985; 25(3): 
190-93. 
51.  Williams MC, Krammer J, O’Brien WF. The value of the cervical 
score in predicting successful outcome of labour induction. Obstet 
Gynecol 1997; 90(5): 784-86. 
 52.  Bidgood KA, Steer PJ. A randomized control study of augmentation 
of labour.1. Obstetric outcome. Br J Obstet Gynecol 1987; 94(6): 
512-17.  
53. Steer PJ, Carter MC, Beard RW. The effect of oxytocin infusion on 
uterine activity leves. In: Studd JWW, Cardozo LD, Gibb DMF, 
editors. The Progress in Obstetrics and Gynecology, 2nd ed.  London: 
Churchill Livingstone; 1989.p.32 – 60.  
54. O’Driscoll K, Foley M, MacDonald D. Active management of 
labour as an alternative to cesarean for dystocia. Obstet Gynecol 
1984; 63(4): 485-90.  
 
 
 
 
Questionnaire 
         Low versus high dose oxytocin in Labour Augmentation  
(1) Name: …………………………………………………………………. 
(2) Age (yrs):            <20                 20-30                ≥ 35  
(3) Occupation                   H.W.                               Employee  
(4) Gestational age (weeks):          37-42                  >42  
(5) Parity:              PG              Para 1 to para 4   
(6) Past history of Augmentation:        Yes                     No  
(7) Pre-Augmentation cervical assessment:  
             Dilated                            Dilated more than 3 cm  
(8) Bishop score: <4             4                  >4  
(9) Vertex presentation: O.A.                O.T.                O.P.  
(10) Membranes:             Intact               Ruptured  
(11) If ruptured when:              A.M                    P.M  
(12) Labour started at :     A.M.                PM  
(13) Augmentation started at:            A.M.                  P.M 
(14) Time of .A.R.M:         A.M.                     P.M  
(15) Syntocinon protocol:          low dose                   high dose  
(16) Cervical assessment after 4hrs. of Augmentation :  
                    Same                     Better  
(17) Decrease of syntocinon dose:               Yes                  No  
(18) Discontinuation of syntocinon infusion:       Yes                  No 
(19) Cause of syntocinon modification of stoppage:  
                   Uterine hypertimulation                        Abnormal F.H.R  
(20) No of times the dose was modified: 1             2-3             >3  
(21) If sedation and/or analgesis used:   Yes                  No  
(22) Maximal dose rate of syntocinon: 1 – 6 mJ/min         8 –12 mU/min  
       16 –30 mU/min           >30mU/min  
(23) Time consume to maximal dose rate (hrs): <4         4-6        >6  
(24) Duration of active phase (hrs): 1-3            4-8             >8  
(25) Duration of labour(hrs):       1-6                   7-12               >12  
(26) Delivery time:      A.M                   P.M  
(27) Mode of delivery: Acc. VD        Ass. Ventose or Forceps           C/S   
(28) Indication of C/S or instrumental delivery:  F.D  
         Maternal Complications            Arrest of labour (dysctocia)  
(29) Post-delivery maternal complications:  Yes                  No  
(30) Neonatal outcome:   Alive                 Dead  
(31) Apgar score:                            1 min               5 min    
(32) Fetal weight (kg):    <3.5                 >3.5  
(33) Resuscitation was needed: Yes                  No 
(34) Adnission to Nursery: Yes                  No 
 
APPENDIX I 
 
 Bishop’s Score (modiefied by Calder et al, 1974)  
(pelvic Score)  
Parameter          0                 1                   2                     3  
1 Dilatation              <1 cm           1-2 cms          2-4 cms            >4 cms 
2 Length                  >4 cms          2-4 cms          1-2 cms            <1 cms  
3 Consistency          Firm              Average          Soft                    -  
4 Position                Posterior        Mid-                 -                        -  
                                                      anterior  
5 Level                  -3                    -2                  -1,0                      +   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           
 
APPENDIX II 
 
 
Apgar Scoring System 
 
    Sign                          0                               1                               2                
1 Heart rate                  Absent                    Below 100                Over 100 
 
2 Respiratory effort     Absent                    Slow, irregular        Good, crying 
 
3 Muscle tone              Flaccid                   Some flexion            Active motion  
                                                                   of extremities  
 
4 Reflex irritability     No response           Grimace                    Vigorous cry  
 
5 Colour                     Blue; pale               Body pink,                 Completey pink  
                                                                  extremities blue  
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
INTRODUTION 
 
  
              The augmentation of labour is a common prevailing obstetric 
policy. It is frequently used in obstetric practice to correct the abnormal 
pattern of ineffective slow labour. It means stimulation of inefficient 
uterine contraction after spontaneous onset of labour.  
  
         Until 1970s, the problem was considered troublesome, but since 
then it has become widespread routine as a part of a movement, 
associated in particular with National Maternity Hospital Dublin, Known 
as Active Management of Labour. While debate raised between 
proponents and opponents, of the active management of labour (or at least 
of its two components, amniotomy and oxytocin augmentation), it rapidly 
moved into routine use, especially in English speaking countries. In 
United States, the use of the procedure was supported by Emmanuel 
Friedman invention of so called partogram; where slow labour declared 
by alert and action lines. The idea is that if labour was slow these lines 
would be crossed and intervention by amniotomy and oxytocin should 
follow.  
 
          Our aim is to reduce the rate of dystocia and consequently 
operative deliveries achieving vaginal delivery as close as possible to the 
natural one without subjecting mother or fetus to more hazards.  
             Definitely, the procedure is not without harm as opponents 
always claim. Hyperstimulation of uterus and resultant abnormal fetal 
heart rate pattern are most common complication that usually necessitate 
modification of the dose rather than complete ceasation of the procedure.  
 
Moreover few studies showed oxytocin augmentation occasionally had 
caused fetal hypoxaemia, hyperbilirubinaemia, hyponatraemia and 
maternal hyponatraemia.  
 
       To date, no universal agreed upon method has come to use 
concerning our subject. For instance, in Dublin and most UK obstetric 
departments they have used early amniotomy and oxytocin infusion 
whenever labour is slow since 1970s. Many in USA do augmentation 
with oxytocin infusate set-up and simultaneous amniotomy as in this 
study. Few prefer late amniotomy and oxytocin infusion when the cervix 
dilated 4 cm or more for fear of infection and a stratified belief that early 
amniotomy and oxytocin will delay labour. No one uses oxytocin alone 
with intact membranes as a method of labour augmentation as this may 
probably end up with amniotic embolism. Additionally, such practice 
may miss the biological advantage of amniotomy.  
       
 Currently, the most effective way to augment and accelerate the latent 
phase of labour artificially is by local administration of prostaglandins 
(PGs) and the duration or frequency of exposure to this agent will depend 
on how far the cervix is ripened, a measure which is best made by Bishop 
score assessment. Our ability to intervene effectively has improved 
steadily with our improved understanding of biological control of human 
labuor. The three intervention currently available are prostaglandins 
which is best administrated vaginally, amniotomy which is ideally done 
when cervix fully effaced and 3 to 4 cm dilated, and oxytocin which is  
best administered by intravenous titration. This order represents the 
logical sequence of their use.  
           In current study, we sought to determine the effectiveness and 
safety of low-dose oxytocin regimen, recommended by (ACOG), 
compared to high-dose oxytocin in augmentation of ineffective labour.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LITERATURE REVIEW 
 
Historical background of labour augmentation:  
                   Over 300 years, the purchase to introduce a method for labour 
stimulation began when Thomas Denman of the Middle Sex Hospital in 
1956 has made a major turn by introducing amniotomy as a method of 
labour stimulation. This method has remained a cornerstone of labour 
stimulation to the present time (Calder, et al)(1).      
                    The isolation of oxytocin by Sir Henry Dale made a glorious 
progress in labour stimulation. In 1909 the first studies carried by 
William Blair on the isolated oxytocin had led to the use of this magic 
hormone in labour stimulation over the next few decades. In 1948 
Theobald et al used oxytocin in infusion set with fixed dose (probably 
low) to stimulate labour. The advent of pure synthetic oxytocics (e.g. 
syntocinon) has enabled oxytocin to be used more effectively to stimulate 
labour.  
                       In 1963, Kieran O’Driscoll of Dublin described a policy of 
labour stimulation named collectively active management of labour. It 
composed of four components (strict criteria for labour diagnosis in 
primigravidae, commitment to never leave a woman unattended in labour, 
early amniotomy and oxytocin augmentation if progress is slow i.e. 
cervical dilatation at rate <l cm/hr). He claimed that it lowered the rate of 
cesarean section and instrumental deliveries, was safer for the baby and 
popular with mothers.  
      
                
 Since 1970s the policy (or at least two of its components early 
aminiotomy and oxytocin augmentation) has become a routine 
management of slow labour in parturients of low parity. 
Contemporaneous with that, the traditional management of soap and 
water enema, hot bath and cinnamon and castor oil was recommended as 
a method of stimulation of labour though it dated over 400 years. This 
combination particularly stimulates contractility of smooth muscles of 
gastrointestinal tract and in some women may simultaneously have 
stimulated myometrial contractions possibly by release of endogenous 
prostaglandins (PGs) from gastrointestinal tissues (Calder et al)(2).    
 
Definition of labour augmentation:  
                (ACOG) defined labour augmentation as stimulation of uterine 
contractions when spontaneous contractions have been considered 
inadequate with resultant failure of progressive cervical dilatation or 
descent of the fetus. Some also consider augmentation to include 
stimulation of contractions following spontaneous rupture of membranes 
without labour (ACOG)(3).    
 
When is labour augmentation indicated:  
             The major indication for labour augmentation as stated by (Cohen 
and Friedman)(4)  is uterine hypotonia i.e. insufficient uterine contractions 
during active phase of labour. (Reynolds and co-workers)(5)  emphasized 
that uterine contraction of normal labour are characterized by gradient of  
 
 
 
 
myometrial activity being greatest and lasting long at fundus (Fundal 
dominance) and diminishing towards the cervix. 
 
            Although more than 50% hypotonic uterine dysfunctional labour 
no obvious cause was detected (Seitchik and co-workers)(6), the remaining 
percentage encountered with primigravidae, cephalopelvic disproportion 
(CPD), fetal malposition and malpresentation. In rare circumstances over-
distention of uterus by twins or hydramnios may contribute to the 
condition as well as rigid cervix either primary (as in senior primigravida) 
or secondly to fibrosis from some cause.  
 
           Also labour augmentation indicated to achieve cervical dilatation 
at rate more than that occurs in normal labour. This is usually needed 
when vaginal delivery is prompted to minimize the risk that could affect 
the mother or fetus if labour prolonged. Example for that is an abruptio 
placenta, although uterus may be hypertonic, especially when cervix is 
well effaced and considerably dilated. The use has been challenged 
against the base that it might enhance the escape of thromboplastin into 
maternal circulation. This has been disgarded by (Pritchard)(7) .  
 
                The use of oxytocin augmentation for hypertonic uterine 
dysfunction (frequent in- co-ordinate contractions) did convert to the 
orderly physiological contraction (Caldeyro-Bracia)(8) . But in general, the 
likelihood of such response is low &risk of enhancing hypertonia is 
considerable (Cohen and Friedman)(4) .  
 
 
 
 
              The procedure is prohibited when no abnormality arises during 
the normal progress of labour (1 cm/hr) because the intervention may 
cause delay and harm rather than hasten and decrease the labour time. 
Also it is contraindicated if there is a contraindication of vaginal delivery 
as in placenta praevia, overt cephalo-pelvic disproportion, transverse lie 
and pelvic obstruction. In other occasions it should be used with high 
caution in grandmultiparae, over-distended uterus, abruptio placentae and 
previous uterine scar.  
 
Incidence:  
                The change in obstetric practice in late 1960s and earl 1970s 
rose the rate of prolonged labour that subjected to augmentation up to 
more than 40% in some countries e.g. USA (Satin et al)(9) . Williams 
reported “ in nearly 20-30% of all pregnancies, woman show difficult 
labour and require labour to be augmented”. In United States, there are 
approximately 4 million deliveries per year and consequently there are 
approximately 1millon such labour augmentation representing 25% 
augmentation rate.  
 
              In Ottawa of Canada (Stewart and colleagues)(10) reported 30% of 
3740 women with labour were given a diagnosis of dystocia and under 
went augmentation.  
 
               In developing countries (Dujordin and co-workers)(11)  described 
in Senegal an augmentation rate of 13% to abnormal labour progress  
 
 
 
 
showing lower incidence than in developed countries.  
              In parkland hospital at Dallas, USA approximately 22% of 
labour is stimulated by oxytocin, and from 1983 to 1990 approximately 
20,000 women were given oxytocin.  
 
             The labour augmentation rates are now increasing probably 
because of either over diagnosis of dystocia or women have developed a 
reproductive disadvantage led to elevation in rate of dystocias incidence.  
 
              A similar incidence of augmentation was described by  ( Boyle  
et al )(12) and (Cardozo et al )(13)  in excess of 40%.  
 
             A low rate of 19.3% was documented at Royal North Shore 
hospital in Sydney, Australia with a rate of 21.8% over all hospitals 
(Mothers & Babies Report)(14) .   
 
Recommendation and guidelines to labour augmentation:  
              Experience has taught the care-deliverers in Parkland Hospital at 
Dallas, as well as many obstetric centers in USA and UK to state clearly 
general as important as specific recommendation that hopefully guide to 
fruitful end of labour augmentation work up:  
 
1) General:  
              The hazard and risks of augmentation should be weighed against 
waiting for spontaneous vaginal delivery. The indication of augmentation 
should be outlined and clear discussion and disclose of risk factors 
(including anticipated obstetrical risk, advantages and limitation of  
 
 
 maternity care services and transport risk) with the pregnant woman and 
her husband prior to augmentation, and informed consent should be 
obtained.  
                Assessment with documentation prior to staring augmentation 
should include:  
 
• Uterine activity: its frequency and duration.  
• Fetal heart and wellbeing.  
• Fetal presentation.  
• Pelvic adequacy.  
• Cervical dilatation, effacement and consistency (Bishop score).  
 
             A qualified registered nurse, familiar with the effects of 
augmentation agents and able to detect both maternal and fetal 
complications, must be available throughout augmentation.  
 
 
2) Delivery of specific care:  
             When augmentation of labour is contemplated, it is important that 
the responsible physician considers where the best conditions can be 
provided for the mother during labour and delivery and for neonatal care, 
and then refers the patient if advisable. Consideration must be given to 
the following: 
 
- Availability of adequately equipped labour and delivery area with 
appropriate resuscitation equipment for both mother and newborn.  
 
- Availability of appropriately trained labour and delivery nursing 
staff to monitor the fetal heart rate, maternal condition (pulse, BP 
….etc) and uterine contraction every 15-30 minutes throughout 
augmentation (Nurse: Patient ratio should be 1:1)  
 
             There is no evidence –based information indicating that operating 
room be a requisite for augmentation of labour. However clinical data 
states that augmentation of a nullipara is associated with twice the chance 
of cesarean delivery compared with spontaneous labour.  
 
                 It is incumbent on rural facilities without cesarean delivery 
capability to determine their local practice and procedure regarding 
augmentation of labour and indications for patient transfer. These 
decisions should take into consideration indications for augmentation, 
antenatal risk factors, method of augmentation, geographic &climatic 
consideration which are all vary from patient to another.  
                   
A tocolytic agent must be available in the event of hypertonic 
uterine contractions.   
 
 
Methods of labour augmentation:  
 
               In literature there are two known methods of labour stimulation; 
surgical and medical. In the past they were considered separate, but in 
modern obstetrics this separation is artificial. (Beazley)(15)  claimed that  
according to a stratified literature, the surgical method (amniotomy) or 
medical one (oxytocin) alone can stimulate labour satisfactory when  
conditions are optimal. Unless both methods used in combination the 
duration of labour remains uncertain.  
 
               While many protocols are widely available & acceptable the use 
of amniotomy in combination with oxytocin infusion is generally 
advocated. Oxytocin infusion is the only drug currently used for labour 
augmentation.  
 
                    Utilization of this approach rapid delivery can be obtained in 
majority of women. Concerning, (Beazley)(15)  said that the ideal method 
for stimulating labour would be one which could produce contraction as 
close as to normal physiological uterine contractions as possible, be free 
from deleterious effects on mother or fetus and be easy and practical to 
use.  
 
                     Recently, in addition to oxytocin use of labour augmentation 
prostaglandins gain popularity in developed countries as the component 
of the speedometer of labour use to accelerate and ripen the cervix during 
the latent phase and consequence augmentation of myometrial 
contractions. 
 
AMNIOTOMY:  
                      The artificial rupture of membranes (A.R.M.) is an old non-
pharmacologic method of labour stimulation and promotion. The 
procedure first introduced by (Thomas Denman,1758) to induce labour. 
Since then, it has become a popular practice in labour rooms of the vast 
majority of hospitals. It promotes labour by the release of endogenous 
prostaglandin in response to local stimulation. In some cases when labour 
is so advanced and Bishop score is high it may be possible to augment 
labour simply by amniotomy. This successfully works more likely in 
multiparous women than primiparae. 
 
                   The approach is particular preferred in grandmultipara 
because of the fear that oxytocin drugs might cause hypotonic uterine 
contractions and consequent disasterous rupture.  
 
                       When amniotomy and oxytocin infusion were the standard 
methods labour augmentation, as in active management of labour, all 
women had amniotomy early and was followed by oxytocin infusion if 
cervical dilatation was slow (less than 1cm/ hr). In certain high-risk cases 
amniotomy may be beneficial to allow early internal fetal monitoring 
when labour ensures. Other wise evidence has shown no overall 
significant benefit of early amniotomy and the membranes can safely be 
left intact until close to delivery unless progress is abnormal (cammu et 
al).(16)  This will minimize the risks of dry labour namely signs of infection 
and cord entanglement that necessitate surgical interference.  
 
              Two decades ago (Patterson)(17)  and (Saleh)(18)  carried out studies 
comparing amniotomy with oxytocin infusion versus amniotomy alone 
favourable cervix lead to a shorter delivery interval, fewer operative 
interference and higher proportion of women delivered with 24 hours 
than with amniotomy alone. This indicates amniotomy alone is often  
inadequate to stimulate and augment labour. In cases studied by (Moldin 
et al)(19)  amniotomy combined with oxytocin infusion resulted in delivery 
interval of 6 hours compared to 9 hours with amniotomy alone. In 
amniotomy combined with oxytocin infusion group 88.7% and 97.7% 
delivered within 12 hours and 24 hours respectively while in cases of 
amniotomy alone 70.4% and 91.8% delivered within 12hours and 24 
hours respectively. In cases studied by (Patterson)(17)  and (Saleh)(18)  
instrumental delivery was 25% and 50% respectively.  
 
                         When the concept is which to start first the amniotomy or 
oxytocin infusion, (Rayburn)(20)  thought it is better to commence oxytocin 
infusion then did amniotomy while (Calder)(1)  was reluctant to give 
oxytocin infusion before amniotomy as it greatly increases the sensitivity 
of myometrium to oxytocin.  
 
OXYTOCIN:  
              Oxytocin has been used for induction of labour for well over half 
a century and remains the major drug for medical augmentation of labour. 
It is an octa peptide hormone released naturally by the posterior pituitary 
gland. Its main action is to stimulate uterine contractions. According to 
the American college of obstricias and Gynaecologists (ACOG)(3)  
oxytocin levels required to produce effective contraction vary widely 
among individual, most likely reflecting unpredictable individual uterine 
sensitivities, variabilities in clearance rates and any pre-existing uterine  
 
 
 
 
 
 
activity. The increase in myometrial oxytocin receptors appears to explain 
the increased sensitivity to oxytocin with increasing gestational age. The 
result of the study conducted by (Fuchs et al )(21)  was in accordance with 
the (ACOG). It showed concentration and distribution of oxytocin 
receptors in myometrial and decidual tissues obtained at hysterectomy or 
cesarean deliveries during pregnancy. It was found that myometrial 
receptors concentration was low at 13 - 17 weeks of pregnancy and rose 
about twelve – fold by 37- 41 weeks after onset of labour. After onset of  
labour either term or preterm, the receptor levels were maximal and 
significantly higher than before labour onset. Myometrial receptor 
concentration in the fundus and the corpus were significantly higher than 
in the lower part of uterine segment and the cervix had the lowest 
concentration. These results - according to the author - are consistent with 
the functional role of endogenous oxytocin in the activation of the human 
uterus during pregnancy and parturition.  
 
Dosage and administration:  
                 Oxytocin infusion for labour stimulation was firs described by 
(Theobald et al.,)(22) (23) (24) in 1948. Since then multiple protocols have been 
suggested. However oxytocin titration method introduced by (Trunbull 
and Anderson) in 1967 is considered the best regimen for oxytocin 
administration.   
 
 
 
 
 
 
 
             The intravenous route is solely the efficient way as subcutaneous, 
intramuscular or intranasal routes are considered inadequate to administer 
oxytocin for augmentation of labour.   
 
             Now, different mechanical and electronic controlled systems and 
pumps are used to adjust the oxytocin infusion rate and dosage. The best 
acceptable one is variable speed pump not gravity fed-drip. The latter 
may accumulate oxytocin in its bottom resulting in bolus infusion, so it 
should be mixed thoroughly every now and then. The former pulsatile 
method, titrated as individual response, dose closely simulate the 
physiological pattern of oxytocin release during spontaneous labour, by 
pumping the drug in 10 minutes pulse infusion.  
 
               The recommended protocols were designed to give lower doses 
of oxytocin at longer interval. According to ((ACOG) technical 
bulletin)(25)  labour stimulation with high dose oxytocin regimen has no 
advantage over a more physiologic low- dose protocol. The high-dose is 
associated with increased risk of uterine hyperstimulation while the low - 
dose in association with slow rate infusion (Increments interval 30 – 60 
minutes) were found appropriate and safe. A fact which was also 
concluded by (Goni et al)(26)  who studied oxytocin increments at 20and 60 
minutes interval.  
 
            Similar results were obtained by (Satin et al.,)(27) (28)  when studied 
both low dose and high dose regimens in 1992 and high regimen 20-40  
 
 
 
minutes intervals in 1994. Also in accordance the conclusion reached by 
(Hourviz et al)(29)  in assessing high versus low dose oxytocin for labour 
stimulation.  
 
The recommended protocol:  
Low-dose protocol:  
              The dose of oxytocin is measured in milliunits (mU) per minute 
based on a standard preparation. The standard infusion concentration, as 
recommended by (ACOG) is 10 units of oxytocin diluted in 1000 ml 
(10mU/ml) of isotonic electrolyte solution usually Hartmanns solution – 
using starting dose of (0.5-2mU/min) with (1-2mu/min) increments every 
30-60 minutes. The solution may be Hartmanns/dextrose or Normal 
saline according to availability and medical need. Forty (40) minutes of 
continuous infusion of a fixed dose of oxytocin is required to reach a 
steady state of plasma concentration (Satin et al.,).(28)  However, failure to 
quickly determine the therapeutic dose of oxytocin significantly increase 
the length of labour and augmentation-delivery time, More than 87% will 
achieve satisfactory uterine activity with (< 4mU/min) while more than 
95% will do so with (7mU/min) of infused oxytocin. The dose 
requirement of a term uterus rarely exceed 20mU/min.  
 
High-dose protocol  
                     In this protocol they use starting dose of (3-6 mU/min) with 
doubling of the infusion rate and dose every (20-40 minutes).  
 
 
 
 
 The maximum rate to reach is not more than (42 mU/min), (Satin et 
al.,).(9)  For doses exceeding (16 mU/min) fetal heart rate auscultation for 1 
minute to 30 second periods after contraction should be done. Secondly, 
hourly maternal pulse and blood pressure should be checked (more 
frequently if indicated). If infusion exceeding 24 hours or other infusions 
are in place, measure serum electrolyte and pay particular attention to 
serum sodium concentration. Also the event of uterine hypertonus 
complication more frequently occurs with this high-dose protocol and so 
the resultant fetal distress.  
 
Prostaglandins (PGs):  
                   PGs firs appeared in the medical literature in 1968 by (Karim 
et al.,).(30)  They used Prostaglandin E2 and F2  for induction of labour. 
Since then (PGs) use has gained enoromous success in clinical 
environment for both cervical ripening and subsequent labour stimulation 
various formulations have been tried in the trials.  
 
             The role of prostaglandins in the reproductive system was heavily 
explored. It is now realized that the PGs members of the group of 
prostanoids, which include also thromboxanes, are probably involved in 
most organs function. They are a family of highly active and structurally 
similar modified unsaturated fatty acids. The group of primary (PGs) 
consists of six members formed by conversion of 3 precursor essential 
unsaturated fatty acids. In reproduction (PGE2) and (PGF2) appear to be  
 
 
 
 
 of major significance and are formed from arachidonic acid via the 
cycloendoperoxides (PGG2) and (PGH2) following the influence of the 
cyclo-oxygenase enzyme system. 
                     They are rapidly metabolised via 15- hydroxy prostaglandin 
dehydrogenase and 13-reductase enzymes which are widely dispersed in 
the body.  
 
                     Although the precise function of (PGs) in the evolution of 
spontaneous parturition remains uncertain, there is convincing evidence 
that they are essential for initiation and normal progress of labour.  
                      (Calder)(2)  stated that in a normal term pregnancy (PGs) are 
activated to provoke cervical ripening and myometrial contractions. 
Increase in (PGs) and their metabolites have been demonstrated both in 
late pregnancy and during cervical dilatation in advanced labour.  
 
                     (Slade et al)(31)  mentioned that they probably act via a second 
mesenger at the amniotic membrane level, which is a rich source of 
arachidonic acid and also to sensitize myometrium to oxytocin. 
Therefore, the use of (PGs) to stimulate labour may thus be considered 
appropriate.  
 
                  There is also a (PGs) surge in the third stages of labour which 
highly likely contributes to the expulsion of the placenta and membranes. 
It helps, therefor, in prevention of postpartum haemorrhage. It was shown 
by (Kennedy et al)(32)  that the incidence of primary postpartum 
haemorrhage appears to be reduced if (PGs) are used as part  
 
 
 of the induction procedures rather than oxytocin alone and that the potent 
oxytocic effect of (PGs) make them of value in the management of 
postpartum haemorrhage. PGs became available in the late 1960, as 
Dinoprost (PGF2) and Dinoprostone (PGE2). The latter is about 5 times 
as potent as Dinoprost in stimulating uterine activity.  
 
                 (Beazley and Alderman)(33)  concluded that neonatal 
hyperbilirubinaemia which can be associated with maternal oxytocin 
infusion of more than 20 units does not appear to be a problem with the 
use of (PGE2).  
 
                Various commercial formulations of (PGE2 = Dinoprostone) 
are now available. The oral and intravenous routes have been abandoned 
because of their side effects, which are related to systemic absorption. 
They are largely supplanted by the local route. The intarvaginal route is 
the one of chioce as it is preferred by both women and clinicians. 
Different protcols, doses and formulations have been tried. They are 
prone to a variety of influences, which may affect absorption. This was 
seen by (Lyndruo)(34)  who reported that quickly absorbed (PGE2) in wax-
based vaginal pessaries is likely to soon cause uterine contractions where 
as PGE2 in low-dose or slowly absorbed preparation, as intracervical gel 
or vaginal lactose tablets, is more likely to only ripen the cervix. The 
ACOG in 1995 recommended intracervical route because it offers the 
advantage of prompting little uterine activity and greater efficacy in very  
 
 
 
 
unripe cervix, but (Calder)(2)  considered it inconvenient use. Indeed, 
intracervical application is hardly possible, because the intracervical 
space is either tiny or open widely and gel leakage to the vagina or 
extramniotic space is more likely and this in turn may produce intense 
myometrial activity. On the other hand, the extra –amniotic 
administration of (PGE2) is thought as effective method of interrupting 
pregnancy because it delivers (PGE2) to the internal cervicalos, the 
region of the cervix from which effacement arises. But, because of its 
invasive nature and more possible uterine hyperstimulation it is not much 
advocated.  
 
                    The recent introduction of a controlled released PGE2 intra 
vaginal insert (cervidile = 10mg Dinoprostone) for cervical ripening and 
labour stimulation has stimulated much interest. The vaginal insert 
provides a lower rate of release than the gel and can be removed should 
hyperstimualtion occur.  
 
                     In a comparative study done by (Rayburn et al.,)(35)  in USA, 
cervidil was found more effective in ripening the cervix and intiating 
active labour by the end of 12-hour dosing period without requiring 
additional oxytocin in both multiparous and mulliparous women when 
compared to multiparous women given multidose of intravaginal PGE2 
gel.  
                    From analysis of oxford data base perinatal trials (Calder)(2)  
stated that it became clear that (PGs)could consistantly improve Bishop  
 
 
 
score, reduce length of labour, reduce cesarean section rate and improve 
neonatal outcome.  
 
                   The duration of labour was shown to be shorter in most of the 
studies (Mackenzie et al.)(36)  reported a mean of 8.1 hours (hrs) in 
primiparae and 4-8 (hrs) in multiparae, while (Calder)(2,1)  shown a mean 
of 10.7 hrs. The length of labour was found in cases studied by 
(Shephered et al.,)(37)  7.8 (hrs) for primiparae and 5.1 hrs for multiparae.  
 
              Uterine hyperstimulation is a serious complication it occurs in 5- 
6% more following (PGs) administration than oxytocin to women 
undergone labour stimulation and occurs more frequently in active phase 
of labour.  
                   Maternal systemic side effects from low-dose (PGE2) (fever, 
vomiting and diarrhea) are negligible as shown in the report of the 
(ACOG technical bulletin).(25)   
 
Misoprostol (PGEI analogue):  
                  Very recently this drug has received increased attention as 
effective cervical ripening agent. Originally, misoprostol was developed 
as an oral drug to treat the gastrointestinal ulceration. It has the advantage 
of being inexpensive, easy to store at room temperature compared to the 
expensive PGE2 preparations.  
 
                   In a comparative study done by (Buser et al)(38)  between 
misoprostol and dinoprostone (PGE2) it was found that the former is  
 
 
 
 more effective in ripening the cervix and stimulating labour. Adversely, 
misoprostol caused an increase in cesarean deliveries and associated with 
uterine hyperstimulation rate of 35.5% compared to 21.5% for 
dinsoporstone group.  
 
               (Alfirevic et al.,)(39)  reviewed five randomised controlled studies 
of oral misoprostol versus other methods for stimulating labour. He 
concluded Oral misoprostol versus placebo reduces the need for oxytocin 
infusion and shortens the time between stimulation of labour and 
delivery. The cesarean deliveries were found 20.2% in oral misoprostol 
group compared to 15.5% in case stimulated by vaginal (PGE2).  
 
The uterine hyperstimulation which is a serious side effect of oral 
misoprostol was found in 37.5% of case compared to 28%for vaginal 
misoprostol.  
 
 Hazards and risks of labour augmentation:  
               Augmentation of labour is not free of hazards both to the mother 
and fetus. The assessment of factors that my lead to these hazards is 
crucial. The risks include:-  
 
(1) Uterine hyperstimulation:  
                There is risk of 1% of uterine hypertonus when labour 
stimulated by Oxytocin infusion or prostaglandins and 0.2% risk of 
sustained tetanic contractions of uterus necessitating urgent tocolysis or 
immediate cesarean delivery (Slade et al).(31)  If not, this will lead to fetal  
 
 
 distress and most serious fetal loss and uterine rupture. This is usually the 
case with prostaglandins (PGs) administration as modulation or stoppage 
of oxytocin infusoin will commonly lead to gradual disapearance of 
uterine hypertonus. It occurs in 35.5% with misoprostol and 21.5% with 
dinoprostone (Buser et al., )(38)   (Satin et al.,)(27)   stated incidence of 52% 
of uterine hyperstimulation for high-dose and 34% for low-dose oxytocin 
augmentation in study of 2788 consecutive pregnencies. It was occurring 
5-6% more with prostaglandin than with oxytocin. The uterine 
hypertonus, by itself, is not necessarily pathologic regarding its outcome. 
The common associations with this risk are inadequate assessment of the 
fetopelvic disproportion degree, malpositiopn and malpresentation of the 
presenting part.  
 
                  In the event of uterine hypertonus, usually seen in association 
with high dose regimens, i.e. six contraction in 10 minutes, contraction 
duration for more than 90 seconds pre-signs of fetal distress; the 
following should be done immediately:-  
 
- Stop oxytocin infusion.  
 
- Change maternal position and correct hypotension.  
 
- Administer oxygen by facemask.  
 
- Consider intravenous salbutamol or Ritodrine administration.  
 
 
 
            When uterine hypertonus or fetal distress has resolved resume the 
oxytocin infusion at half the previous rate. Increase will be after 30 
minutes only if there has been no further evidence of uterine 
hypertonicity or fetal distress. Moreover, in the presence of recurrent 
severe variable or late decelerations consideration should be given to fetal 
scalp blood sampling for pH.  
 
(2) Fetal distress:  
                Fetal distress (F.D) occurs when fetus deprived from its oxygen 
requirements (fetal hypoxia) causing the affected one to reflexely grasp in 
muconeum. This is the case when labour is prolonged or uterus is 
hyperstimulated. (El –Quarmalawi et al )(40)  repoted in a study of labour 
stimulation by PGE2 versus oxytocin a 16% incidence of fetal 
bradycardia with oxytocin leading to immediate cesarean delivery. (Satin 
et al)(27)  reported an incidence of 4% with oxytocin augmentation.  
 
(3) Infection:  
                It constitutes a little appreciable risk in obstetric practice as 
amnionitis can always be detected with prolonged labours more than 30 
hours after amniotomy.  
 
(4) Neonatal hyperbilirubinaemia:  
                It is a well-recognized risk of high dose oxytocin administration 
during labour especially in a prolonged one. The role of oxytocin 
administration during labour in aetiology of neonatal hyperbilirubinaemia  
 
 
 
 
has been a subject of much discussion especially in British literature. 
Many investigators have confirmed the association between the use of 
oxytocin and neonatal hyperbilirubinaemia.  Initially, no mechanism was 
identified to explain clearly the cause of oxytocin – related 
hyperbilirubinaemia until lately (Buchan)(41)  concluded that it is the 
vasopressin-like action of oxytocin that cause osmotic swelling of 
erythrocytes leading to decreased deformability and some rapid 
destruction. Maternal and neonatal hyponatraemia caused by the above 
action can be minimized or preferably prevented by the use of saline or at 
lesser extent glucose with saline as vehicle for oxytocin. (Leylek et al.,)(42). 
Also, dexamethasone injection is used as a prophylaxis from RBCs 
destruction and sudsequent neonatal hyperbilirubinaemia.  
 
                 Despite of the above hazards, babies delivered with low Apgar 
scores are reported to be trivial and when so there is often a cause, which 
is actually not related to oxytocin infusions. Apgar score at 5 minute and 
less than 4 was found in 6 cases out of a large number of 1976womem 
augmented by (Satin et al.,)(27) . (Seitchik and Castillo)(43)  reported 3 
neonates of 1-minute Apgar score less than 7 of 129 augmented cases, 
each has specific aetiology and was unrelated to oxytocin infusion (cord 
entanglement, mid-forceps extraction and epidural anaesthesia –
associated with maternal hypotension). In the same study they found no 
neonate with 5- minute Apgar score less than 8. The percentage is little 
higher with oxytocin induction as described by (Hourviz, et al.,)(29)  who  
 
 
 
 
 
 found 1 minute Apgar score <7 in 4.8% of 179 cases, and 5-minute Apgar 
score <7 in 5% of cases induced by (Krammer et al).(44)   
 
               In oxytocin augmented patients, in spite of prolonged labour, on 
significant increase in asphyxial perinatal death, neonatal seizures and 
abnormal neonatal neurological behaviour in 30.874 term primigravidae 
(Cahill et al)(45) . Also, (Akoury et al.,)(46) (47)  had the same conclusion in a 
controlled prospective study of 1080 nulliparae, that no satisfactory 
significant birth asphyxia or perinatal morbidity between augmented 
group (high-dose oxytocin) and non-oxytocin group (Thorp et al.,)(48) 
showed that on adverse effect of high-dose oxytocin augmentation on 
umbilical cord blood gas values at delivery.  
 
(5) Need for analgesia:  
                Augmented labours increased the need for analgesia and 
subsequent impact in labour duration with high incidence of instrumental 
delivery and cesarean section.   
 
(6) Failure of augmentation and operative delivery:  
             This usually results from failure to progress due to an overlooked 
fetopelvic disproportion, dystocia, chorioamnionitis or fetal distress that 
urge cesarean delivery (Satin et al.,)(27)  declared a rate of 14.5% of 
cesarean section and 14% of instrumental deliveries for failure or 
augmentation.  
 
 
 
 
                      The failure to progress means failure of active uterine 
contractions (Active phase of labour) to dilate the cervix over a 
reasonable period of time (Raybun)(20)  denoted at least 2 hours period 
while (Dwight et al)(49)  extended oxytocin augmentation for active phase 
labour arrest to at least 4 hours before resorting to operative delivery. 
They found it was effective and safe with 92% of 542 women delivered 
vaginally compared with 83% vaginal deliveries when time restricted to 
only two hours.  
 
Reasons of failure of augmentation:  
                    Failure of Augmentation has been attributed to many factors 
influencing the process and course of labour. The factors thought to be 
involved include the type of oxytocin regimens used, primiparit, high 
maternal age, the type of augmentation method, lack of oxytocin 
receptors and poor selection of patients.  
 
A) Oxytocin regimen type:  
                  Low-dose Oxytocin regimens with long incremental intervals 
are associated with less augmentation failure rates due to less incidence of 
uterine hyperstimulation 33% & fetal distress 4% (Seitchil & Castillo)(43) 
and (Satin et al).(27)   Contrariwise, the cesarean section rate for dystocia in 
relation of oxytocin dose regimens & incremental intervals was 12% for 
low-dose regimen with long incremental intervals (40- minutes) versus 
9% for high-dose regimen with short intervals (20- minutes). In contrast 
the incidence of uterine hyperstimulation 55% and fetal distress 6% are  
 
 
 increased with high-dose oxytocin with short incremental intervals and 
resultant increase in cesarean section rates. High-dose oxytocin regimens 
shortened labour up to 3 hours (Satin et al)(27)  but did not lower cesarean 
or instrumental deliveries in meta-analysis of randomized controlled trial 
of 5.100 women with slow labour (Dwight et al.,).(49)  same of trials 
suggested high-dose oxytocin regimens increased the need for epidural & 
prolongation of labour (Dwight et al.,)(49)  with the resultant liability for 
cesaran section.  
 
B) Primiparity:  
                As in normal labours, parous women in augmented labours tend 
to have a shorter course of labour than nulliparae. This fact has 
highlighted the necessity of reviewing nulliparous and multiparous 
women as biologically different groups in term of labour performance. 
The cervix in nulliparous women will not dilate to 4cm before it has 
already been effaced, where in multiparae cervical dilatation of 4cm often 
occurs before effacement is complete. The nulliparous women are the 
largest group with firm rigid cervix which increases the likehood of failed 
augmentations or prolonged exhausting labour. (Moldin et al)(19)  reported 
a difference in success rate of labour stimulation by amniotomy and 
oxytocin; 94.9% for multiparae achieved vaginal delivery within 12hours 
compared to 79.4% for the nulliparous women. The difference was found 
to be bigger in a similar group of patients stimulated in the same study by  
 
 
 
 
amniotomy alone with higher success in multiparae because of already 
dilated cervix.  
 
C) The Type of Augmentation method:  
                     (Seitchik et al.,)(6)  demonstrated that aminiotomy alone 
appeared to enhance dilatation of well-dilated cervices and slowed that of 
less dilated ones. The failure rate was as high as 20% to achieve a 
satisfactory dilatation rate (1 cm or more/hr) when aminiotomy alone was 
used. The combination of aminiotomy and oxytocin infusion especially in 
less-dilated cervices leads to high rate of vaginal deliveries 88.7% 
compared to 70.4% for aminiotomy alone (Moldin et al.,)(19)  fewer 
instrumental deliveries 25% to 50% respectively (Patterson)(17)   & 
(Salih).(18)      
 
 
D) Insensitive Target organs:  
                       The women in whom failure of progress of stimulated 
labours was encountered, the level of circulating oestradiol concentration 
were found to be lower than those with successful stimulated labours 
(Marchenzie)(36) . This may not facilitate the rise in Prostaglandin F2 (PGF) 
metabolic in circulation which appears to be necessary for progressive 
labour to occur. On other hand (Calder)(I)  pointed out that in some cases 
whereas the cervix is firm, rigid and thick (unfavorable) there may well 
be an excess of (Prostaglandin dehydrogenate) (PGDH) activity or some 
enzyme activities that contribute to an unfavorable cervix. Likewise,  
 
 
 
 
 women in preterm labour may have (PGHD) deficiency provoking their 
labour process. 
 
E) Lack of oxytocin receptors:  
                       (Fuchs et al)(21)  found a relation between oxytocin receptors 
in human uterus and failed stimulation of labour. He studied 
concentration and distribution of oxytocin receptors in myometrial and 
decidual tissues obtained at cesaerean section or hysterectomy during 
pregnancy. He found that after the onset of labour, either preterm or term, 
the receptor levels are maximal and significantly higher than before 
labour onset. While in cases of failed stimulation of labour with oxytocin 
the levels were significantly lower tan in spontaneous normally 
progressing labour.  
 
F) High maternal age:  
                      (Lyndup)(34)  listed high maternal age as one of the predictive 
factors related to disadvantageous labour stimulation. Fetal malposition is 
more common in such old ladies and so are fetal malpresentation and 
both predispose to failed stimulation of labour. Mechanical factors that 
delay and obstruct labour should be excluded before the decision of 
augmentation is made.  
G) Inappropriate selection of patients:  
                  Inappropriate selection of women undergoing augmentation of 
labour without clear indication-as hyptonic uterus-was found to be a  
 
 
 
 reson for failure of progress. (Arulkumaran et al)(50)  studied 1057 cases 
subjected to stimulation. They analyzed the indications for stimulation 
and revealed that a fair number of cased had debatable obstetric 
indications. Also, they suggested that tailoring stimulation of labour to 
cervical score and indication might reduce the cesarean section rate for 
failed progress of labour.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
OBJECTIVES 
 
A) General: 
      To assess the effectiveness and safety of low- compared to high- dose 
protocol in augmentation of labour.  
 
B) Specific : 
 
1- To determine the incidence of uterine hyperstimulation                         
and fatal distress in both protocols. 
 
2-  To measure the duration of labour in each protocol. 
 
3- To determine the rate of operative delivery (C/S                       
and instrumental delivery) in both groups.    
 
 
 
 
 
 
 
 
 
 
  
MATERIALS & METHODS 
 
 
 
                  This experimental study was carried out at New Omdurman 
Maternity Hospital, in the period from March 30, to October 1,2000. The 
hospital is especially designed as maternity institute supported by 
Khartoum State ministry of health. The hospital capacity is around 110 
beds. The nearly twenty Obstetrics & Gynaecology house officers and 
seven registrars are supervised by seven consultants. Annually, not less 
than four thousand deliveries take place in the hospital. The number of 
total deliveries within the period of the study was 1976. The study 
population consisted of women attending the lobour ward for delivery.  
             One hundred forty- nine parturient were selected to the study. 
The inclusion criteria were pregnant women who had gestational age of 
37 to 43 weeks, singleton pregnancies with cephalic presentation with no 
contraindication to augmented vaginal delivery and were given diagnosis 
of ineffective labour as her cervix at least 3-4cm on admission and did not 
dilate progressively within two hours.   
                    Pregnancies complicated by viscous meconium, sever 
hydramnios, or parity of five or more were excluded. All subjects were  
 
 
 
 
 
 
 
admitted to labour room and selected randomly to one protocol of 
oxytocin augmentation. Our study of low-versus high-dose oxytocin 
protocols for labour stimulation consisted of low-dose protocol which 
begins with I mU/min, dose and incremental increases of I mU/min at 30-
minute intervals up to 6 mU/min, then 2mU/min incremental, increases 
up to 12mU/min, then 4 mU/min increments up to a maximum 
40mU/min. The high-dose protocol included a starting dose of 3 mU/min 
at 30 minute intervals with 3mU/min increments up to 12mU/min, then 
6mU/min increments at the same intervals up to a maximum 42mU/min. 
 
                The incremental increase was reduced from 6 to 3 mU/min in 
the presence of uterine hyperstimulation after halving the reaching dose. 
Recurrent hyperstimulation was managed by ImU/min oxytocin 
increments. All pregnancies eligible for labour stimulation during the 6 
months study period were managed according to these protocols. 
 
             The whole procedure and aim of the study were well explained to 
each parturient and written consent of agreement was taken. All were 
seen by a consultant obstetrician and gave permission for the procedure. 
 
            For data collection, a details standard, questionnaire was 
designed. The history notes, the clinical review and examination of each 
subject as well as labour diagnoses were all carried out by the author.  
 
 
 
 
 
 
            The infusate prepared by the author, for either regimen comprised 
2 units of synthetic oxytocin (syntocinon) diluted in 500 ml of 5% 
glucose with 0.9% solution given concentration of 4 mU/ml, the regimen 
was administrated by house officers specially trained for that purpose. 
Oxytocin infused by drop drip-set in a rate according to the intended 
protocol. Assuming that I ml = 20 drops, we started low-dose regiment 
with 5 drops/min (I mU/min)  and high-dose regimen with 15 drop/min 
(3mU/min) every 30 minutes till 3 contractions of 30-45 sec duration 
each in 10 minutes were achieved. The infusate was turned off in the 
presence of uterine hyperstimulation 6 contractions or more, or duration 
of 90 seconds or more in 10 minutes or fetal heart rate abnormalities. 
Oxytocin was readjusted to one-half the previous dose and then titrated 
after 30 minutes interval at half rate. 
 
                 The progress of labour was monitored on WHO designed 
partogram. The fetal heart rate was monitored by intermittent auscultation 
every 30 minutes in the first stage, and every 5 minutes in the second 
stage of labour.  
 
                 The labouring women were nursed throughout the first stage in 
the lateral position. Oral fluids were some time allowed. Sedation and 
analgesia were given per need. Bishop score was recorded before the 
commencement of the procedure; we chose the cervical assessment as 
determining component of successful labour stimulation (Williams  
et al) (51). Reassessment of the cervix performed after 2 or 4 hours after  
 
 
 
augmentation, with bearing down and full dilatation of the cervix the 
parturient was transferred to the delivery table and vaginal delivery  
managed by the senior mid-wife on duty in the lithotomy position. 
Instrumental delivery was indicated for fetal distress, maternal exhaustion 
or prolonged second stage of labour.  
             Cesarean section was performed for fetal distress in the first stage 
of labour, maternal complications necessitating immediate delivery or 
failure of progress. The failure of augmentation was considered if the 
uterine contractions had not led to further cervical dilatation during active 
phase of labour over at least 4-hours period.  
              Perinatal records was filled and completed by the attending 
house officer including the mode and time of delivery, neonate weight, 
Apgar score at 1-and 5-minutes after delivery, if resuscitation and 
admission to the nursery was necessary. 
            The placenta was delivered by controlled cord traction. The 
patient was a observed for 2 hours after delivery in the labour ward before 
her transfer to postnatal ward where most of the patients were discharged 
on the next day. 
        The data was collected in a discrete, transferred to a master sheet, 
coded and fed to a microcomputer. Statistical analysis was performed 
using the computer statistical package minitab. 
      Appropriate statistical tests were used for comparable variables. X2 
test and fisher exact test of probability were used stratification of data 
controlling for demographic variables were achieved where appropriate. 
Two –tailed P values of 0.05 or less were considered significant. 
 
 
RESULTS 
 
               A total of 149 women required one of the two syntocinon 
protocols 91.9% of the ages were within 20-34 years with a mean of 27.4 
years for the whole study group (Table1, Fig.1). Most of the women were 
housewives 92.6%and only 7.4% employee. 
 
            All pregnancies were term cited between 37 and 42 weeks. Except 
5 women (3-4%) who were post-term dating more than 42 weeks. While 
age, occupation and parity had nothing to do with the mode of delivery, 
the gestational age was the only character of pregnancy that significantly 
affect the mode of delivery (Table 2,3). 
 
           The significance between nulliparae and high-dose; and primiparae 
or more and low-dose may be attributed to the process of randomization 
and/or the feeling of safety among the staff when they relate the low-dose 
to primiparae or more and vice versa (Table4, Fig.4). This was shown by 
a higher rate of cesarean delivery among post-terms (Table5, Fig.3). 
 
         On the other hand, the dilated cervices (59.7%) and subsequent high 
Bishop scores were (more than 4, 94%) significantly associated with high 
vaginal deliveries (Table 6&7). 
          It was found that the cervical assessment was highly significant 
(P=0.000) than Bishop score (P=0.023) indicating that the former is the 
most important factor in predicting the expected vaginal delivery.  
 
 
 
 
These cervices were assessed again after the intervention administrates by 
one of the protocols. Most of them were improved (96.6%) and only 5 
cases (3.4%) showed no improvement. Consequently, this was reflected 
on a high significant rate of vaginal deliveries (85.9%) (JP=0.000)   
(Table 8,Fig.5). 
More than half of the remaining 5 cases, which showed no improvement, 
ended by cesarean delivery (Table 8). Moreover, it was found no relation 
between the protocol used and the cervical improvement (Table 9). 
 
            Significantly, larger doses were used in high-dose group (Table 
10). Three cases required more than 30 mU/min, two of them had 
cesarean deliveries (Table 11). 
 
            The time consumed to reach the maximum dose of syntocinon 
was insignificantly shorter in high-dose protocol (Table 12).  
 
           This resulted in a shorter duration of labour in the high-dose group 
than the low-dose one; but significantly at expense of an increased rate of 
uterine hyperstimulation (14.1% Vs 25.5%) (P=0.020) (Table 13 & 14). 
However, uterine hyperstimulation resulted in insignificant fetal heart 
rate abnormalities (2.7% vs 2.6%) that urged immediate operative 
delivery (instrumental or cesarean), no adverse neonatal effects were 
observed after delivery (Table 13 & 15; Fig. 6 &7). 
 
          The syntocinon infusion, in the presence of uterine 
hyperstimulation, was modified rather than completely stopped. The 
modification was significantly higher in high-dose group (12.7% vs 
24.1%) (P=0.004) (Table 16 & 17) (Fig. 8 & 9). Most of the cases 
(69.1%) required a maximum dose of less than (8 mU/min) in both 
protocols (43% vs. 26.2%) (P=0.000) while only 2% required more than 
(30mU/min) which entirely cited in high-dose group (Table 10, Fig.10). 
 
There was a significant inverse correlation between the maximum 
dose and the probability of attaining vaginal delivery. Of 103 cases who 
required less than (8 mU/min), 101 delivered vaginally (Table 11);  
 (P=0.000). 
 
Duration of labour was insignificant shorter by 4 hours in high-
dose group (Table 14, Fig.11) (P=0.544). The mean duration for the high-
dose was 8 hours and for the low-dose was 12 hours. 
                
  A total of 128 women delivered vaginally constituted (85.9%) of 
whole study group. No significant difference was found between the two 
protocols (41.6%) vs.44.3%) (Table 19, Fig.12). 
 
There were 8 light ventose or forceps delivery equal to (5.4%). 
Five were in low-dose (3.4%) and there were in high-dose (2%) (Table 
19, Fig.12). The indications were 4 suspicious fetal distress(2.7%) and 4 
(2.7%) for maternal complications either due to maternal exhaustion or 
medical problem. The low incidence of instrumental delivery among the 
high-dose group was insignificant (Table 19).  
 
The incidence of cesarean delivery among the study group was 
(8.7%), with (4.7%) among low-dose and (4%) among high-dose group.  
 
 
 
The variation between two groups is trivial and insignificant (Table 19, 
Fig. 12). 
 
             The cesarean delivery indications were 4 for fetal distress (2.7%), 
1 for maternal exhaustion and distress (0.6%) and 8 for arrest of labour 
(5.4%). The syntocinon protocol had no significant influence in 
developing these indications (Table 21, Fig. 13). 
 
            These indications significantly affected the mode of delivery as 
dystocia was entirely led to cesarean delivery and maternal exhaustion 
was almost managed by instrumental delivery (Table 21 & 22, Fig. 13 
&14). 
 
           Again high-dose protocol was indirectly and, more important, 
insignificantly associated with low cesarean section for dystocia and low 
instrumental deliveries for maternal complications (Table 21, Fig. 13). 
 
             Post delivery maternal complications occurred in 3 cases, one in 
low-dose and another 2 in high-dose. They occurred within the first 6 
hours after delivery. One was minor post-partum haemorhage (<1,000ml) 
due to retained placental tissue in a women delivery vaginally. She was 
treated by manual removal of the tissue and ergometrine. No blood 
transfusion was needed. The remaining two were vaginal and cervical 
tears due to the  forceps delivery treated by successful haemostatic 
sutures. This correlation between postpartum complications and forceps 
deliveries was highly significant (P=0.000) while no relation to the 
protocol used (P=0.633). 
 
 
            All babies were born alive. No neonatal death reported in the 
study group. No 1 min Apgar Score less than 4 was recorded. Three cases 
of high-dose protocol (2%) had 1 min Apgar Score equal to 4, however, 
no case of 1 min Apgar Score equal to 4 reported in low-dose group 
(Table 23) (P=0.006). Moreover, 1 min Apgar Score of 4 was 
significantly found in operative deliveries (2 instrumental (1.3%) and 1 
cesarean section (0.6%) (Table 24). Fortunately, after 5 minutes no score 
less than 8. The 5 babies (3.4%) who scored 8, 3 (2%) were 
insignificantly in high-dose group (P=0.504) and 4 (2.7%) were 
significantly operative deliveries (2 (1.3%cesarean section) (Table25) 
(P=0.000). 
 
            14 neonates needed resuscitation. No significant differences 
between the two protocols regarding this need. The significant differences 
was found between modes of delivery (P=0.000) (2 (1.3%) vaginal 
delivery,5 (3.4%) instrumental delivery and 7 (4.6%) cesarean delivery) 
(Table 26, Fig. 15). 
 
              All babies who were admitted to the nursery were from operative 
route of delivery (2 (1.3%) instrumental and 2 (1.3%) cesarean) given a 
significant (P= 0.000) when compared to vaginal route (Table 27, 
Fig.16).  
            143 (96%) of babies weighing 3.5 kg or less while 6% weigh 
more than 3.5 kg. The fetal weight had an effect on mode of delivery 
giving significant probability of vaginal delivery when weighing 3.5kg or 
less (125 (84%) (P=0.034) (Table 28).  
 
 
 
  
   Table 1.   Age distribution among the study groups 
                        according to syntocinon protocol   
 
Age groups              Low dose                  High dose                   Total 
 (years)       
< 20                         20 (1.40%)               06 (4.00%)              008 (5.40%) 
 
20 - 34                     72 (48.3%)               65 (43.6%)              137 (91.9%) 
 
≥35                          00                             04 (2.70%)                 04 (2.70%) 
 
 
Total                       71(49.70%)              75 (50.30%)             149 (100%) 
 
 
 
Mean age =27.4 years.   
 
 
 
 
 
 
 
 
  
     Table 2. Relation between syntocinon protocol and   
                                        occupation  
 
Occupation                    Low dose               High dose               Total                             
House wives                68 (45.7%)             70 (46.9%)            138 (92.6%)  
 
Employee                   06 (04.0%)             05 (03.4%)             011 (07.4%)  
 
 
Total                          74 (46.7%)              75 (50.3%)             149 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
         
Table 3. Relation between syntocinon protocol  
                               and gestational age  
 
Gestational             Low dose              High dose                          Total  
37 – 42                   70 (46.9%)            74 (49.7%)                   144 (96.6%)  
 
> 42                        04 (02.8%)            01 (00.6%)                   005 (03.4%) 
 
 
Total                       74 (49.7%)             75 (50.3%)                  149 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 
Table 4.  Relation between syntocinon protocol and parity 
 
 
Parit                  Low dose                    High dose                     Total    
PG                     15 (10.1%)                  44 (29.5%)                   59 (39.6%)  
 
Para 1 - 4           59 (39.6%)                  31 (20.8%)                   90 (60.4%)  
 
 
Total                  74 (49.7%)                  75 (50.3%)                   149 (100%) 
  
 
  
     
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 5. Relation between gestational age and mode of delivery 
  
  
 
 
Gestational              VD                  Ventose                 CS                      Total  
                                                          Or 
 age                                                    
                                                       forceps   
37 – 42                     127                    07                     10                          144 
                             (85.2%)            (4.7%)                (6.7%)                  (96.6%)  
 
>42                          001                  001                     03                          005 
                             (0.7%)             (0.7%)               (2.0%)                    (3.4%) 
 
 
Total                        128                  8                     13                           149 
                             (85.9%)         (5.4%)              (8.7%)                    (100%)  
 
 
 
 
 
 
 
 
 
 
 
  
Table 6. Effect of pre-augmentation cervical assessment on 
mode of delivery 
 
Cervical                              VD                       Ventose or                     CS  
Assessment                                                        Forceps                 
 
Dilated 3 cm                   56 (37.6%)              2 (1.3%)                        2 (1.3%)  
 
Dilated > 3 cm                72 (48.3%)               6 (4.0%)                      11 (7.4%)  
        
 
Total                               128 (85.9%)             8 (5.4%)                       13 (8.7%)  
 
  
 
P = 0.0000 highly significant      
  
 
 
 
 
 
 
 
 
       
 Table 7.  Correlation between bishop score and  
                              mode of delivery  
 
Bishop               VD               Ventose or               C/S                  Total  
score                                        Forceps  
<4                    0                        0                          0                        0  
 
4                  006 (4.0%)            0                          3 (2.0%)           9 (6.0%)  
 
>4                 122                      8                         10                      140  
                   (81.9%)              (5.4%)                 (6.7%)               (94%)                                     
             
 
Total           128                        8                          13                     149  
                  (85.9%)              (5.4%)                   (8.7%)              (100%)           
    
 
P =0.023 Significant   
 
 
 
 
 
 
 
 
  
 
Table 8.    Correlation between cervical assessment after  
             2-4 hours augmentation and mode of delivery 
 
Cervical                   VD               Ventose or                  C/S               Total  
assessment                                     Forceps              
 
Same                     02 (1.3%)              0                      3 (2.0%)          5 (3.4%) 
 
 
Better                      126                       8                          10               144  
                             (84.6%)              (5.4%)                  (6.7%)          (96.6%)     
                                                                                          
 
Total                     128                          8                      13                    149  
                           (85.9%)                (5.4%)                 (8.7%)               (100%)  
                                                        
  
  P = 0.0000 Highly significant  
 
 
 
 
 
 
 
 
  
 
Table 9. Correlation between cervical assessment after 2 or 4 
                        hours augmentation & syntocinon protocol 
 
Cervical assessment                      Low dose                           High dose 
Same                                             02 (1.3%)                            03 (2.0%)  
 
 
Better                                             72 (48.3%)                          72(48.3%)  
 
 
Total                                             74 (94.7%)                            75 (50.3%)  
 
     
  
P = 0.506  not significant  
   
 
 
 
 
 
 
 
 
 
 
  
 
    Table 10.  Maximal dose by syntocinon protocol  
 
Dose rate                             Low dose                                High dose 
1-     6 mU/min                  64 (43.0%)                              39 (26.2%)  
 
8-    12mU/min                  06 (04.0%)                              25 (16.8%)  
 
16-  30mU/min                 04 (2.70%)                               08 (5.40%)  
 
>30  mU/min                              0                                    03 (2.0%) 
 
 
 
Total                                74 (49.7%)                              75 (50.3%) 
 
          
 
P = 0.0000 significant  
 
 
 
 
 
 
 
 
  
Table 11. Correlation between maximum syntocinon dose 
and mode of delivery 
 
Maximum Dose                     VD                    Ventose or                  CS  
                                                                          Forceps  
 
1- 6 mU/min                       101 (67.8%)             2 (1.3%)                     0  
 
8 - 12 mU/min                   024 (16.1%)              2 (1.3%)                 5(3.4%)  
 
16- 30 mU/min                  002 (1.3%)                4 (2.7%)                 6 (4.0%)  
 
> 30                                  001 (0.7%)                  0000                     2 (1.3%)  
 
 
Total                                128 (85.9%)              8 (5.4%)                13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
  
Table 12. Time consumed per hour to max. dose by  
                                    syntocinon protocol  
 
Time consumed                         Low dose                          High dose   
Per hour 
<4                                          64 (43.0%)                           42 (28.2%)  
 
4-6                                        06 (04.0%)                           25 (16.7%)  
 
>6                                        04 (02.7%)                            08 (05.4%) 
 
 
Total                                   74 (49.7%)                            75 (50.3%) 
 
 
 
P =0.0000 significant  
  
 
 
 
 
 
 
 
 
 
  
 
 Table 13. Causes of syntocinon modification or stoppage  
                                 by syntocinon protocol  
 
Cause of syntocinon                      low dose                        High dose  
No uterine or FHR                        52(34.9%)                       35(38.5%)  
abnormality  
Uterine hypertimulation               18(12.1%)                        36(24.2%)  
 
Abnornal FHR                             01(0.7%)                           02(1.3%)  
 
Uterine hypertimulation &         03(2.0%)                            02(1.3%)  
Abnormal FHR                          
 
Total                                          74(49.7%)                         75(50.3%)  
 
 
 
P =0.020  significant  
      
  
 
 
 
 
 
 
  
     
Table 14.  Correlation between duration of labour and  
                              Syntocinon protocol  
 
Duration of labours /hours                    Low dose                 High dose                  
1-6                                                          08                             32  
 
7-12                                                        54                              36  
 
> 12                                                         12                              07 
  
 
Total                                                        74                              75  
 
 
 
P = 0.544 not significant  
 
Mean duration of labour = 10 hrs  
Mean duration of labour in low dose = 12 hrs  
Mean duration of labour in high dose = 8 hrs   
 
 
 
 
 
  
 
     Table 15.    Correlation between Causes of syntocinon 
                    modification or stoppage and mode of delivery 
 
Cause of  
syntocinon  
VD   Ventose or  
      forceps 
C/S 
No uterine or FHR                  75 (50.3%)         3 (2.0%)           9 (6.0%)  
abnormality  
 
Uterine hyperstimulation          53 (35.6%)         1 (0.7%)          0   
 
Abnormal FHR                            0                      2 (1.3%)           1 (0.7%)  
Uterine hyperstimulation           
& Abnormal FHR                        0                      2 (1.3%)           3 (2.0%)  
Total   128 (85.9%)     8 (5.4%)   13 (8.7%)  
    
 
P = 0.0000 highly significant  
   
 
 
 
 
 
 
 
  
 
Table 16. Decrease syntocinon dose by syntocinon protocol  
 
 
Decrease syntocinon                     Low dose                         High dose  
Yes                                             19 (12.7%)                        36 (24.1%)  
 
 
No                                             55 (36.9%)                          39 (26.2%)  
 
 
Total                                        74 (49.7%)                           75 (50.3%)  
 
 
  
P = 0.004 significant  
  
 
 
 
 
 
 
 
 
 
 
 
  
 
    Table 17.   Correlation between times the dose was  
                             modified and syntocinon protocol  
 
Dose modified                              Low dose                            High dose                           
1                                                     54 (36.3%)                         38 (25.5%)  
 
 
2- 3                                                 20 (13.4%)                         20 (13.4%) 
  
> 3                                                  00                                       17 (11.4%) 
  
 
Total                                               74 (49.7%)                         75 (50.3%) 
 
 
 
 
   
P = 0.0000 highly significant  
  
  
 
 
 
 
 
 
 
 
        
Table 18.   Discontinuation of syntocinon infusion by  
                                   syntocinon protocol  
 
Discontinuation                      Low dose                      High dose  
Yes                                         05 (03.4%)                    06 (04.0%)  
 
 
No                                         69 (46.3%)                     69 (46.3%)  
 
 
Total                                     74 (49.70%)                   75 (50.3%)  
                              
 
 
P = 0.498 not significant  
 
 
 
 
   
     
   
 
 
 
 
 
         
 
Table  19.   Association between mode of delivery  
                                   and syntocinon protocol  
 
Mode of delivery                       Low dose                    High dose  
Vaginal delivery                        62 (41.6%)                    66 (44.3%)  
 
 
 
Forceps or Ventose                  05 (03.4%)                      03 (02.0%)  
 
 
C/S                                            07 (04.7%)                      06 (04.0%)  
 
 
 
Total                                         74 (49.7%)                     75 (50.3%)  
 
 
 
 
P = 0.415 Not significant  
 
 
 
 
 
  
 
Table 20. Sedation need in relation to syntocinon protocol  
 
Decrease syntocinon                    Low dose                       High dose  
Yes                                               25 (16.7%)                    50 (33.6%)  
 
 
No                                              49 (33.0%)                      25 (16.7%)  
 
 
Total                                           74 (49.7%)                      75 (50.3%)  
 
 
 
P = 0.0000 Significant  
     
 
 
 
 
 
   
  
 
  
 
 
  
 
        Table 21.   Operative delivery indications by   
                                    syntocinon protocol  
 
Operative indication                  Low dose                           High dose   
FD                                              4 (2.7%)                            4 (2.7%)  
 
 
Maternal complication              3 (2.0%)                             2 (1.3%)  
 
 
Arrest of labour                        5 (3.3%)                               3 (2.0%)  
 
 
Total                                        12 (8.0%)                              9 (6.0%)  
 
 
 
P = 0.845 Not significant  
 
 
 
 
 
 
 
 
  
Table 22. Operative delivery indications by mode of delivery  
 
 
Operative indication                        Ventose or Forceps               C/S  
FD                                                      4 (2.7%)                             4 (2.7%)  
 
 
Maternal complication                      4 (2.7%)                              1 (0.6%)  
 
 
Arrest of labour                                  0                                        8 (5.4%)  
    
 
Total                                              8 (5.4%)                                 13 (8.7%)  
 
 
 
P = 0.0000 significant  
 
   
 
 
 
 
 
 
 
  
  Table 23. One minute Apgar score by syntocinon protocol  
 
1 min Apgar score                           Low dose                       High dose  
 
4/10                                                 00                                    03 (2.0%)  
 
6/10                                                 06 (4.0%)                        02 (1.3%)  
 
8/10                                                 61 (41.1%)                        70 (47.0%)  
 
10/10                                                70 (4.6%)                         00  
 
 
 
Total                                                 74 (49.7%)                       75 (50.3%)  
                     
 
 
P = 0.006 significant  
 
 
 
 
 
 
 
  
    Table 24. One minute Apgar score by mode of delivery  
 
Apgar score                          VD                   Ventose or                        CS  
At 1 min                                                         forceps 
4/10                                         0                      1 (0.6%)                      2 (1.3%)  
 
6/10                                002 (1.30%)              3 (2.0%)                      3 (2.0%)  
 
8/10                               120 (80.6%)               3 (2.0%)                      8 (5.4%)  
 
10/10                              006 (4.00%)               1 (0.6%)                         00  
 
        
 
Total                              128 (85.9%)               8 (5.4%)                    13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
  
   Table 25. Five minute Apgar score by mode of delivery  
 
Apgar score                      VD                     Ventose or                 CS  
At 5 min                                                       Forceps                     
 
8/10                           001 (0.6%)                2 (1.3%)              02 (1.3%)  
 
 
10/10                       127 (85.3%)                6 (4.0%)              11 (7.4%)  
 
 
Total                        128 (85.9%)                8 (5.4%)              13 (8.7%)  
 
 
  
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 26.  Need for resuscitation by mode of delivery 
 
Resuscitation                   VD                       Ventose or                 CS  
Need                                                               Forceps  
 
Yes                              002 (1.3%)                 5 (3.4%)                07 (4.6%)  
 
No                               126 (84.6%)               3 (2.0%)                 06 (4.0%)  
 
 
Total                           128 (85.9%)                8 (5.4%)                 13 (8.7%)  
 
 
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 27.   Admission to nursery by mode of delivery 
 
Admission to                      VD                    Ventose or               CS  
Nursery                                                          forceps         
 
Yes                                     00                    2 (1.4%)                   02 (1.3%)  
 
 
No                                 128 (85.9%)          6 (4.0%)                   11 (7.4%)  
 
 
Total                            128 (85.9%)            8 (5.4%)                  13 (8.7%)  
 
  
 
P = 0.0000 highly significant  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 28.  Correlation between  Birth weight and mode of  
                                         delivery  
 
Birth weight (kg)           VD              Ventose or Forceps           CS  
 
≤ 3.5                           125 (83.9%)             7 (4.8%)                 11 (7.4%)  
 
 
 
> 3.5                          003 (2.00%)               1 (0.6%)                 02 (1.3%)  
 
 
Total                         128 (85.9%)                8 (5.4%)                  13 (8.7%)  
 
     
 
 
P = 0.034 significant    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
Fig. (1) Age distribution 
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Fig. (3) Relation between gestational 
age and mode of delivery
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 Fig. (4) Relation between 
syntocinon protocol and parity
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Fig. (6) Causes of 
syntocinon modification or 
stoppage by syntocinon 
protocol
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Fig. (7) Correlation between 
causes of syntocinon modification 
or stoppage and mode of delivery
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Fig. (8) Decrease syntocinon 
dose by syntocinon protocol
19
36
55
39
0
10
20
30
40
50
60
Low dose High dose
syntocinon protocol 
N
u
m
be
r 
o
f c
a
s
e
s
 
(W
o
m
e
n
)
Yes (decreased)
No (not
decreased)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9) Correlation between times 
the dose was  modified and 
syntocinon protocol
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Fig. (10) Maximal dose reached 
by syntocinon protocol
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Fig. (11) Correlation between 
duration of labour and syntocinon 
protocol
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Fig. (12)   Association between mode 
of delivery and syntocinon protocol
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Fig. (13)  Operative delivery 
indications by syntocinon protocol
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Fig. (14) Operative delivery 
indications by mode of delivery 
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 Fig. (15)  Need for resuscitation by 
mode of delivery 
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Fig. (16)   Admission to nursery by 
mode of delivery
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DISCUSSION 
 
 
  
              To our knowledge, the purpose of this experimental study was to 
answer the question which oxytocin-dose regimen is beneficial to 
augment labour? The answer is both. 
              High-dose oxytocin clearly had several advantages when used to 
augment ineffective labour. Labour duration was 4 hours shorter with 
high-dose than low-dose infusion. This is not far from the one quoted by 
(Satin et al.)(27)  in a similar study. He reported more than 3 hours shorter 
with high-dose regimen. A similar result stated by (Bidgood)(52) &  
(Steer).(53)   
The seemingly high rates of uterine hyper-stimulation in both study goups 
reflect adherence to a onservative and precise definition of uterine hyper-
stimulation as contractions of 2 minutes’ duration or greater; or six or 
more contraction in 10 minutes. This definition is taken by most obstetric 
units in UK and USA (Satin et al .,).(27)  Although labour augmentation 
with high-dose was associated with sigificantly more frequent uterine 
hyper-stimulation (14.1%vs.25.5%); there is no apparent adverse 
maternal or fetal sequale from this as (Cahill et al.,),(45) (Hourviz et al.,)(29)  
and (Satin et al.,)(27)  confirmed this finding.  (Satin et al.,)(27)   descibed 
incidence of (39% vs. 52%); (P<0.0001). The rate of abnormal fetal heart 
rate sounds in the form of late or variable bradycaridia, or severe 
tachycardia (>180 b/min)was the same for both groups (2.7%). 62.5% of 
these abnormal patterns were significantly associated with uterine hyper- 
 
 
 
 
 stimulation confirming their significant correlation (P=0.020). Compared 
to (Satin et al.,)(27) , incidence of fetal heart rate abnormalities was 
significantly different in both groups being 3% for low-dose-similar to 
our result- and 6% for high-dose.(Bidgood et al.,)(52)  described 1.7%  for 
high-dose in association of 37% of uterine hyper-stimulation. These 
differences may reflect deferent sensitivities to occurrence of  uterine 
stimulation among the same three studies (low-versus high-dose oxytocin 
uterine hyper-stimulation is dependent on the uterine density of oxytocin 
receptors which differ from patient to another.  
 
               Majority of patients delivered vaginally and spontaneously (not 
by instrument) 85.9%. (14.6%) in low-dose and 44.3% in high-dose. 86% 
delivered within the first 12 hours; most of them primigravidae. The 
difference was significant between two protocols regarding labour 
duration of 6 hours or less being the majority in high-dose group 
(21.4%vs.5.4%). The bulk was in low-dose group (44.3% vs.28.9%) 
when labour lasted more than 6 hours (Cardozo et al.,)(13) , (Satin et al .,)(9)  
and (Bidgood) (52)    & ( Steer)(53)    had similar reports.  
 
             The patients delivered by vetose or forceps were 8 giving rate of 
(5.4%). (3.4%) in low-dose versus (2%) in high-dose. The indications 
were fetal distress (50%) and maternal exhaustion (55%). (Satin et       
al.,)(27) desdcribed rate of around (4% vs.3%) (Bidgood) (52)   &( Steer)(53)  
gave high rates (15% vs. 13%) most probably because of common usage of  
 
 
 
high forceps during that time. To say that high-dose reduces the rate of 
instrumental vaginal delivery it needs large randomized control trial. 
 
               The rate of c/s was 8.7 giving insignificant higher incidence 
(4.7%) among low-dose group than high-dose group (4%). In 
concordance (Boyle et al;)(12), (Cardozo et al;)(13)  and (Bidgood) (52) & 
(Steer)(53)  decided rates of (8.6%), (8.7%), (8.9%) respectively. 
 
               The close similar results, despite the different size above 
mentioned studies, support the conclusion that oxytocin augmentation 
dose not reduce the overall rate of C/S unless dystocia was strongly and 
specifically considered in association with high-dose regimen. 
 
                 The common indication was dystcia  (61.5%). (38.5%) in low-
dose and (23%) in high-dose. This might insignificantly show the reduced 
rate of c/s done for dystocia in high-dose group as clearly declared by 
(Satin et al.,)(27) and before that (O'Discoll et al.,)(54) . In contrast, high-
dose augmentation did not increase the incidence of cesareans done for 
fetal distress (2.7% vs.2.7%). 
 
                Age of the patient and her parity will affect the rate  of cesarean 
deliveries in both groups. Nulliparas are younger; usually have long 
labours, less cervical score and rigid not tested pelvic floor leading to 
high possibility of cesarean delivery. The (Calder et al.,)(1)  supported that, 
as viewing nulliparae (usually young) and multiparae (usually old)     as 
biologically different groups in respect of labour performance, since  
 
 
 
the cervix in nullipara will not dilate before it is effaced where in 
multipara cervical dilatation of 4 cm often occurs before effacement is 
completed. Hence, the former is more liable to c/s than the latter. 
 
                 As in the literature, no perinatal deaths can be attributed to 
oxytocin augmentation and hence is our study. There was some degree of 
neonatal morbidity. Low Apgar scores were greatly and significantly 
referred to instrumental vaginal deliveries (1.3%) and less likely to 
cesarean section. No low morbid score found with vaginal deliveries, 
which needed admission to the nursery. Higher number of the babies 
delivered by operative means needed resuscitation and in some, 
admission to the nursery than those delivered by normal vaginal route. 
This may be interpreted by that the operative delivery was frequently 
used for already distressed baby, in addition to the risk of the procedure 
itself. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
CONCLUSION & RECOMMENDATIONS 
 
 
                   The results of this clinical trial indicate that labour 
augmentation with a high-dose oxytocin is clearly superior to a low-dose 
protocol. Although high-dose protocol associated with high rate of uterine 
hyperstimulation, it shorted labour without adverse affects on mother or 
baby. 
                   There is no difference between low-and high-dose protocols 
as far as mode of delivery is concerned. Vaginal delivery occurred in 
most of women followed by cesarean and instrumental deliveries, 
successfully. 
                   Neonatal resuscitation or nursery admission is mainly 
attributed to the operative delivery rather than the dose used. This is 
probably due to the cause of the operative intervention. 
                   This  small randomized trial of a group of women in slow 
inefficient labour highlights the need for a large randomized control  
 double blinded study to support its claims.  
                    In our set-up, it is strongly recommended the introduction 
and usage of oxytocin-infusion pump to overcome the technical 
difficulties encountered in the dose adjustment and concentration. 
This will avoid the occurrence of haemodilution, hyponatraemia and 
hence the neonatal hyperbilirubinaemia.     
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Questionnaire 
         Low versus high dose oxytocin in Labour Augmentation  
(1) Name: …………………………………………………………………. 
(2) Age (yrs):            <20                 20-30                ≥ 35  
(3) Occupation                   H.W.                               Employee  
(4) Gestational age (weeks):          37-42                  >42  
(5) Parity:              PG              Para 1 to para 4   
(6) Past history of Augmentation:        Yes                     No  
(7) Pre-Augmentation cervical assessment:  
             Dilated                            Dilated more than 3 cm  
(8) Bishop score: <4             4                  >4  
(9) Vertex presentation: O.A.                O.T.                O.P.  
(10) Membranes:             Intact               Ruptured  
(11) If ruptured when:              A.M                    P.M  
(12) Labour started at :     A.M.                PM  
(13) Augmentation started at:            A.M.                  P.M 
(14) Time of .A.R.M:         A.M.                     P.M  
(15) Syntocinon protocol:          low dose                   high dose  
(16) Cervical assessment after 4hrs. of Augmentation :  
                    Same                     Better  
(17) Decrease of syntocinon dose:               Yes                  No  
(18) Discontinuation of syntocinon infusion:       Yes                  No 
(19) Cause of syntocinon modification of stoppage:  
                   Uterine hypertimulation                        Abnormal F.H.R  
(20) No of times the dose was modified: 1             2-3             >3  
(21) If sedation and/or analgesis used:   Yes                  No  
(22) Maximal dose rate of syntocinon: 1 – 6 mJ/min         8 –12 mU/min  
       16 –30 mU/min           >30mU/min  
(23) Time consume to maximal dose rate (hrs): <4         4-6        >6  
(24) Duration of active phase (hrs): 1-3            4-8             >8  
(25) Duration of labour(hrs):       1-6                   7-12               >12  
(26) Delivery time:      A.M                   P.M  
(27) Mode of delivery: Acc. VD        Ass. Ventose or Forceps           C/S   
(28) Indication of C/S or instrumental delivery:  F.D  
         Maternal Complications            Arrest of labour (dysctocia)  
(29) Post-delivery maternal complications:  Yes                  No  
(30) Neonatal outcome:   Alive                 Dead  
(31) Apgar score:                            1 min               5 min    
(32) Fetal weight (kg):    <3.5                 >3.5  
(33) Resuscitation was needed: Yes                  No 
(34) Adnission to Nursery: Yes                  No 
 
APPENDIX I 
 
 Bishop’s Score (modiefied by Calder et al, 1974)  
(pelvic Score)  
Parameter          0                 1                   2                     3  
1 Dilatation              <1 cm           1-2 cms          2-4 cms            >4 cms 
2 Length                  >4 cms          2-4 cms          1-2 cms            <1 cms  
3 Consistency          Firm              Average          Soft                    -  
4 Position                Posterior        Mid-                 -                        -  
                                                      anterior  
5 Level                  -3                    -2                  -1,0                      +   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           
 
APPENDIX II 
 
 
Apgar Scoring System 
 
    Sign                          0                               1                               2                
1 Heart rate                  Absent                    Below 100                Over 100 
 
2 Respiratory effort     Absent                    Slow, irregular        Good, crying 
 
3 Muscle tone              Flaccid                   Some flexion            Active motion  
                                                                   of extremities  
 
4 Reflex irritability     No response           Grimace                    Vigorous cry  
 
5 Colour                     Blue; pale               Body pink,                 Completey pink  
                                                                  extremities blue  
                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
